

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number  
**WO 03/037349 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/54**,  
31/495, 31/50, A61P 11/06, 17/06, 29/00, 37/00

(21) International Application Number: PCT/EP02/09596

(22) International Filing Date: 28 August 2002 (28.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
01125394.5 31 October 2001 (31.10.2001) EP

(71) Applicant (for all designated States except US): **MERCK  
PATENT GMBH** [DE/DE]; Frankfurter Strasse 250,  
64293 Darmstadt (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EGGENWEILER**,  
Hans-Michael [DE/DE]; Erbacher Strasse 49, 64287  
Darmstadt (DE). **WOLF**, Michael [DE/DE]; Nussbau-  
mallee 59, 64297 Darmstadt (DE).

(74) Common Representative: **MERCK PATENT GMBH**;  
Frankfurter Strasse 250, 64293 Darmstadt (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF

(57) Abstract: The invention relates to the use of type 4 phosphodiesterase inhibitors (PDE IV inhibitors) to treat diseases and to combinations of PDE IV inhibitors with other drugs.

WO 03/037349 A1

## **Type 4 phosphodiesterase inhibitors and uses thereof**

5       The invention relates to the use of type 4 phosphodiesterase inhibitors (PDE IV inhibitors) to treat diseases and to combinations of PDE IV inhibitors with other drugs.

10       Reference is made to WO 01/57025 which discloses special pyrimidine derivatives as PDE IV inhibitors, their use for treating diseases and combinations with other drugs.


15       The invention was based on the object of discovering new uses of compounds having valuable properties, especially those which may be used to prepare medicaments.

20       It has been found that the preferred PDE IV inhibitors and their salts combine very valuable pharmacological properties with good tolerability for the treatment of diseases.

25       The present invention is concerned with the use of the preferred PDE IV inhibitors described below and as defined in claims 1, 2 or 3. In the following these compounds are called "preferred compounds".

30       Accordingly, the invention provides in particular for the use of  
a)    compounds of formula I disclosed in EP 0763534

- 2 -



5

in which

10

B is an aromatic heterocycle having 1 to 4 N, O and/or S atoms, bonded via N or C, which can be unsubstituted or mono-, di- or trisubstituted by Hal, A and/or OA, and can also be fused to a benzene or pyridine ring,

15

Q is absent or is alkylene having 1-6 C atoms,

X is CH<sub>2</sub>, S or O,

R<sup>1</sup> and R<sup>2</sup> in each case independently of one another are H or A,

R<sup>3</sup> and R<sup>4</sup> in each case independently of one another are -OH, OR<sup>5</sup>,

20

-S-R<sup>5</sup>, -SO-R<sup>5</sup>, -SO<sub>2</sub>-R<sup>5</sup>, Hal, methylenedioxy,

-NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>5</sup> or -NR<sup>5</sup>R<sup>6</sup>,

R<sup>5</sup> and R<sup>6</sup> in each case independently of one another are A, cycloalkyl having 3-7 C atoms, methylenecycloalkyl having 4-8 C atoms or alkenyl having 2-8 C atoms,

25

A is alkyl having 1 to 10 C atoms, which can be substituted by 1 to 5 F and/or Cl atoms and

Hal is F, Cl, Br or I


and their stereoisomers and physiologically acceptable, salts and solvates;

30

b) compounds of formula I disclosed in WO 99/65880

35

- 3 -




in which

- 10 B is a phenyl ring which is unsubstituted or mono- or polysubstituted by  $R^3$ ,
- Q is absent or is alkylene having 1-4 C atoms,
- 15  $R^1, R^2$  each independently of one another are  $-OR^4$ ,  $-S-R^4$ ,  $-SO-R^4$ ,  $-SO_2-R^4$  or Hal,
- $R^1$  and  $R^2$  together are also  $-O-CH_2-O-$ ,
- 20  $R^3$  is  $R^4$ , Hal, OH,  $OR^4$ , OPh,  $NO_2$ ,  $NHR^4$ ,  $N(R^4)_2$ ,  $NHCO-R^4$ ,  $NHSO_2-R^4$  or  $NHCOOR^4$ ,
- $R^4$  is A, cycloalkyl having 3-7 C atoms, alkylencycloalkyl having 5-10 C atoms or alkenyl having 2-8 C atoms,
- 25 A is alkyl having 1 to 10 C atoms, which can be substituted by 1 to 5 F and/or Cl atoms and
- Hal is F, Cl, Br or I,
- and their physiologically acceptable salts and solvates;

25

c) compounds of formula I disclosed in WO 99/08047



35

in which

- 4 -

$R^1, R^2$  in each case independently of one another are  $-OH$ ,  $OR^5$ ,  $-S-R^5$ ,  $-SO-R^5$ ,  $-SO_2-R^5$  or Hal,

$R^1$  and  $R^2$  together are also  $-O-CH_2-O-$ ,

5  $R^3$  is  $NH_2$ , NHA, NAA' or a saturated heterocycle having 1 to 4 N, O and/or S atoms which can be unsubstituted or mono-, di- or tri-substituted by Hal, A and/or OA,

Q is absent or is branched or unbranched alkylene having 1-10 C atoms,


10  $R^5$  is A, cycloalkyl having 3-7 C atoms, alkylencycloalkyl having 4-8 C atoms or alkenyl having 2-8 C atoms,

A, A' in each case independently of one another are alkyl which has 1 to 10 C atoms and which can be substituted by 1 to 5 F and/or Cl atoms and

15 Hal is F, Cl, Br or I,

and the physiologically acceptable salts and solvates thereof;

20 d) compounds of formula I disclosed in WO 98/06704



in which

30 B is A, OA,  $NH_2$ , NHA, NAA' or an unsaturated heterocycle which has 1 to 4 N, O and/or S atoms and which can be unsubstituted or mono-, di- or trisubstituted by Hal, A and/or OA,

35 Q is absent or is alkylene having 1-6 C atoms,

- 5 -

5  
10  
15  
R<sup>1</sup>, R<sup>2</sup> in each case independently of one another are -OH, OR<sup>5</sup>,  
-S-R<sup>5</sup>, -SO-R<sup>5</sup>, -SO<sub>2</sub>-R<sup>5</sup>, Hal, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>5</sup> or -NR<sup>5</sup>R<sup>6</sup>,  
R<sup>1</sup> and R<sup>2</sup> together are also -O-CH<sub>2</sub>-O-,  
R<sup>3</sup>, R<sup>4</sup> in each case independently of one another are H or A,  
R<sup>5</sup>, R<sup>6</sup> in each case independently of one another are A, cycloalkyl  
having 3-7 C atoms, methylenecycloalkyl having 4-8 C atoms  
or alkenyl having 2-8 C atoms,  
A, A' in each case independently of one another are alkyl which  
has 1 to 10 C atoms and which can be substituted by 1 to 5 F  
and/or Cl atoms and  
Hal is F, Cl, Br or I,  
and the stereoisomers and physiologically acceptable salts and solvates  
thereof;


20  
25  
30  
35  
e) compounds disclosed in WO 00/59890  
1-(4-ureidobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-  
tetrahydropyridazine,  
1-(4-nicotinoylaminobenzoyl)-3-(3-propoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
1-(4-trifluoroacetamidobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
1-(4-ethoxycarbonylaminobenzoyl)-3-(3-propoxy-4-  
methoxyphenyl)-1,4,5,6-tetrahydropyridazine,  
1-(4-isopropoxycarbonylaminobenzoyl)-3-(3-ethoxy-4-  
methoxyphenyl)-1,4,5,6-tetrahydropyridazine,  
1-(4-propoxycarbonylaminobenzoyl)-3-(3-ethoxy-4-  
methoxyphenyl)-1,4,5,6-tetrahydropyridazine,  
1-(4-nicotinoylaminobenzoyl)-3-(3,4-dimethoxyphenyl)-4-ethyl-  
1,4,5,6-tetrahydropyridazine,  
1-(4-ethoxycarbonylaminobenzoyl)-3-(3,4-dimethoxyphenyl)-4-  
ethyl-1,4,5,6-tetrahydropyridazine and

- 6 -

1-(4-acetamidobenzoyl)-3-(3,4-dimethoxyphenyl)-4-ethyl-1,4,5,6-tetrahydropyridazine,

and their physiologically acceptable salts and solvates;

5 f) compounds of formula I disclosed in DE 19604388



15 in which

$R^1, R^2$  in each case independently of one another are H or A,  
 $R^3, R^4$  in each case independently of one another are -OH, OA,  
 -S-A, -SO-A, -SO<sub>2</sub>-A, Hal, methylenedioxy, -NO<sub>2</sub>, -NH<sub>2</sub>,  
 -NHA or -NAA',

20 A, A' in each case independently of one another are alkyl having 1 to 10 C-atoms, and which can be substituted by 1 to 5 F and/or Cl atoms, cycloalkyl having 3-7 C atoms or methylenecycloalkyl having 4-8 C atoms,

25 B is -Y-R<sup>5</sup> oder -O-Y-R<sup>5</sup>,

Q is absent or is alkylene having 1-4 C atoms,

Y is absent or is alkylene having 1-10 C atoms,

X is CH<sub>2</sub> or S,

30 R<sup>5</sup> is NH<sub>2</sub>, NHA, NAA' or is a saturated 3-8 membered hetero-cycle having at least one N atom, and wherein other CH<sub>2</sub> groups optionally may be replaced by NH, NA, S or O, which can be unsubstituted or monosubstituted by A or OH,

35 Hal is F, Cl, Br oder I


- 7 -

and the stereoisomers and physiologically acceptable salts and solvates thereof;

g) compounds of formula I disclosed in DE 19932315

5

10



15

in which

$R^1, R^2$  in each case independently of one another are H, OH, OA, SA, SOA,  $SO_2A$ , F, Cl or  $A'_2N-(CH_2)_n-O-$ ,

20

$R^1$  and  $R^2$  together are also  $-O-CH_2-O-$ ,

$R^3, R^4$  in each case independently of one another are H, A, Hal, OH, OA,  $NO_2$ , NHA,  $NA_2$ , CN, COOH, COOA, NHCOA,  $NHSO_2A$  or  $NHCOOA$ ,

25

$R^5, R^6$  in each case independently of one another are H or alkyl having 1 to 6 C atoms,

A is alkyl having 1 to 10 C atoms, which can be substituted by 1 to 5 F and/or Cl atoms,

30

is cycloalkyl having 3-7 C atoms, alkylencycloalkyl having 5-10 C atoms or alkenyl having 2-8 C atoms,

$A'$  is alkyl having 1, 2, 3, 4, 5 or 6 C atoms,

n is 1, 2, 3 or 4,

Hal is F, Cl, Br or I,


35

and their physiologically acceptable salts and solvates;



- 8 -

h) compounds of formula I disclosed in EP 0723962



10 in which

R¹ and R² in each case independently of one another are H or A,

R³ and R⁴ in each case independently of one another are -OH,  
 -OR¹⁰, -S-R¹⁰, -SO-R¹⁰, -SO₂R¹⁰, Hal, methylenedioxy, -NO₂,  
 -NH₂, -NHR¹⁰ or -NR¹⁰R¹¹,

15

R⁵ is a phenyl radical which is unsubstituted or mono- or  
 disubstituted by R⁶ and/or R⁷,

Q is absent or is alkylene having 1-6 C atoms,

20

R⁶ and R⁷ in each case independently of one another are -NH₂,  
 -NR⁸R⁹, -NHR¹⁰, -NR¹⁰R¹¹, -NO₂, Hal, -CN, -OA, -COOH or  
 -COOA,

R⁸ and R⁹ in each case independently of one another are H, acyl having  
 1-8 C atoms which can be substituted by 1-5 F and/or Cl  
 atoms, -COOA, -S-A, -SO-A, -SO₂A, -CONH₂, -CONHA,  
 -CONA₂, -CO-COOH, -CO-COOA, -CO-CONH₂,  
 -CO-CONHA or -CO-CONA₂,

25

A is alkyl having 1 to 6 C atoms which can be substituted by 1-5  
 F and/or Cl atoms,

30

R¹⁰ and R¹¹ in each case independently of one another are A, cycloalkyl  
 having 3-7 C atoms, methylenecycloalkyl having 4-8 C atoms  
 or alkenyl having 2-8 C-atoms

35

and

Hal is F, Cl, Br or I,


- 9 -

and their physiologically acceptable salts and solvates;

i) compounds of formula I disclosed in EP 0738715

5

10



in which

$R^1$  and  $R^2$  in each case independently of one another are H or A,

$R^3$  and  $R^4$  in each case independently of one another are -OH, -OR<sup>10</sup>,  
-S-R<sup>10</sup>, -SO-R<sup>10</sup>, -SO<sub>2</sub>R<sup>10</sup>, Hal, methylenedioxy, -NO<sub>2</sub>, -NH<sub>2</sub>,  
-NHR<sup>10</sup> or -NR<sup>10</sup>R<sup>11</sup>,

$R^5$  is a phenyl radical which is unsubstituted or mono- or  
disubstituted by  $R^6$  and/or  $R^7$ ,

Q is absent or is alkylene having 1-6 C atoms,

$R^6$  and  $R^7$  in each case independently of one another are -NH<sub>2</sub>,  
-NR<sup>8</sup>R<sup>9</sup>, -NHR<sup>10</sup>, -NR<sup>10</sup>R<sup>11</sup>, -NO<sub>2</sub>, Hal, -CN, -OA, -COOH or  
-COOA,

$R^8$  and  $R^9$  in each case independently of one another are H, acyl having  
1-8 C atoms which can be substituted by 1-5 F and/or Cl  
atoms, -COOA, -SO-A, -SO<sub>2</sub>A, -CONH<sub>2</sub>, -CONHA, -CONA<sub>2</sub>,  
-CO-COOH, -CO-COOA, -CO-CONH<sub>2</sub>,  
-CO-CONHA or -CO-CONA<sub>2</sub>,

A is alkyl having 1 to 6 C atoms which can be substituted by 1-5  
F and/or Cl atoms,

$R^{10}$  and  $R^{11}$  in each case independently of one another are A, cycloalkyl  
having 3-7 C atoms, methylenecycloalkyl having 4-8 C atoms  
or alkenyl having 2-8 C-atoms


35

and

- 10 -

Hal is F, Cl, Br or I,  
and their physiologically acceptable salts and solvates;

5 j) compounds of formula I disclosed in EP 0 618 201



in which

15  $R^1$  and  $R^2$  in each case independently of one another are H or A,  
 $R^3$  and  $R^4$  in each case independently of one another are OH, OA, SA,  
 SOA,  $SO_2A$ , Hal, methylenedioxy, cycloalkyloxy with 3-7  
 C-atoms or  $O-C_mH_{2m+1-k}F_k$ ,

20  $R^5$  is  $-NR^6R^7$  or  $-N(CH_2)_n$ ,

wherein one  $CH_2$ -group may be replaced by oxygen,

$R^6$  and  $R^7$  in each case independently of one another are H or A,

25 Q is alkylen with 1-6 C-atoms,

A is alkyl with 1-6 C-atoms,

Hal is F, Cl, Br or I,

m is 1, 2, 3, 4, 5 or 6,

n 3, 4, 5 oder 6,


30 k 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 oder 13

and their physiologically acceptable salts and solvates;

k) compounds of formula I disclosed in EP 0 539 806

35

- 11 -



5

in which

- $R^1$  and  $R^2$  in each case independently of one another are H or A,  
 $R^3$  is H, OA or  $O-C_mH_{2m+1-n}X_n$ ,  
 $R^4$  is  $-O-C_mH_{2m+1-n}X_n$ ,  
 $X$  is F or Cl,  
 $A$  is alkyl with 1-6 C-atoms,  
 $m$  is 1, 2, 3, 4, 5 or 6 and  
 $n$  is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13  
 and their physiologically acceptable salts and solvates;  
 for preparing a medicament for treating a subject suffering from a disease  
 or condition mediated by the PDE4 isozyme in its role of regulating the  
 activation and degranulation of human eosinophils.

20

Preferably, the invention provides for the use of

a) compounds disclosed in EP 0763534:

25

2-(3-nicotinoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(2-nicotinoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

30

2-(4-nicotinoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(3-nicotinoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

35

2-(2-nicotinoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

- 2-(4-nicotinoylaminobenzyl)-6-(3-methoxy-4-trifluoromethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-nicotinoylaminobenzyl)-6-(3-methoxy-4-difluoromethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 5 2-(4-nicotinoylaminobenzyl)-6-(3-methoxy-4-fluoromethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-nicotinoylaminobenzyl)-6-(3-difluoromethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 10 2-(4-nicotinoylaminobenzyl)-6-(3-trifluoromethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-nicotinoylaminobenzyl)-6-(3-fluoromethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 15 2-(4-nicotinoylaminobenzyl)-6-(3-methoxy-4-ethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-nicotinoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 20 2-(4-nicotinoylaminobenzyl)-6-(3-hydroxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-nicotinoylaminobenzyl)-6-(4-methylsulfonylphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 25 2-(4-nicotinoylaminobenzyl)-6-(4-methyleneoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-nicotinoylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 30 2-(3-nicotinoylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-nicotinoylaminophenethyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-nicotinoylaminophenethyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 35 3-(4-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(3-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-  
1,3,4-thiadiazin-2-one,

3-(2-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-  
1,3,4-thiadiazin-2-one,

5 3-(4-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

3-(3-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

10 3-(2-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-  
trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

15 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-  
difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-  
6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

20 3-(4-nicotinoylaminobenzyl)-5-(3-difluoromethoxy-4-  
methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-trifluoromethoxy-4-  
methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

25 3-(4-nicotinoylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-  
6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazin-2-one,

30 3-(4-nicotinoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

35 3-(4-nicotinoylaminobenzyl)-5-(3-hydroxy-4-methoxyphenyl)-6-  
ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(4-methylsulfonylphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

- 3-(4-nicotinoylaminobenzyl)-5-(4-methyleneoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,
- 5 3-(3-nicotinoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,
- 3-(4-nicotinoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,
- 10 3-(4-nicotinoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 15 3-(3-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(2-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 20 3-(4-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(3-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 25 3-(2-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 30 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 35 3-(4-nicotinoylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,

- 3-(4-nicotinoylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-  
6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-oxadiazin-2-one,
- 5 3-(4-nicotinoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(3-hydroxy-4-methoxyphenyl)-6-  
ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 10 3-(4-nicotinoylaminobenzyl)-5-(4-methylsulfonylphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(4-methyleneoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-oxadiazin-2-one,
- 15 3-(4-nicotinoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-  
6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(3-nicotinoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-  
6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 20 3-(4-nicotinoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-  
dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-oxadiazin-2-one,
- 25 2-(3-nicotinoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-  
tetrahydropyridazin-3-one,
- 2-(4-isonicotinoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-pyrazinecarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,
- 30 2-(4-(isoxazole-5-carbonylamino)benzyl)-6-(3-ethoxy-4-  
methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-nicotinoylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,
- 35 2-(4-nicotinoylaminobenzyl)-6-(3,4,-dimethoxyphenyl)-2,3,4,5-  
tetrahydropyridazin-3-one, hydrochloride,



- 16 -

and their stereoisomers and physiologically acceptable, salts and solvates;

b) compounds disclosed in WO 99/65880

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-methoxybenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-methylbenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)benzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-3,4-dichlorobenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-trifluoromethylbenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-3-chlorobenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-fluorobenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-butoxybenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-pentoxybenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-ethoxybenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-3,4-dimethoxybenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-3-methylbenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-3-methoxybenzoyl-3-carboxamide,

and their physiologically acceptable salts and solvates;

c) compounds disclosed in WO 99/08047

3-dimethylaminopropyl {4-[3-(3-ethoxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,

5 N-methylpiperidin-4-yl-{4-[3-(3-ethoxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,

3-dimethylaminopropyl {4-[3-(3-isopropoxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,

3-dimethylaminopropyl {3-[3-(3-ethoxy-4-methoxyphenyl)-  
10 1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,

3-dimethylaminopropyl{3-[3-(3-cyclopentyloxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,

N-methylpiperidin-4-yl-{3[3-(3-cyclopentyloxy-4-methoxyphenyl)-  
15 1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,

3-dimethylaminopropyl{3-[3-(3-propyloxy-4-methoxyphenyl)--  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,

3-dimethylaminopropyl{4-[3-(3,4-diethoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,

20 N-methylpiperidin-4-yl-{4-[3-(3,4-diethoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,

3-dimethylaminopropyl{3-[3-(3,4-dimethoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate

25 3-dimethylaminopropyl{4-[3-(3,4-dimethoxyphenyl)-1,2,3,4-tetra-  
hydropyridazin-1-ylcarbonyl]phenyl}carbamate,

and the physiologically acceptable salts and solvates thereof;

30 d) compounds disclosed in WO 98/06704

1-(4-nicotinoylaminobenzoyl)-3-(3,4-dimethoxyphenyl)-1,4,5,6-  
tetrahydropyridazine,

1-(3-nicotinoylaminobenzoyl)-3-(3,4-dimethoxy-phenyl)-1,4,5,6-  
tetrahydropyridazine hydrochloride,

35 1-(2-nicotinoylaminobenzoyl)-3-(3,4-dimethoxy-phenyl)-1,4,5,6-  
tetrahydropyridazine,

- 1-(4-nicotinoylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
1-(3-nicotinoylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
5 1-(4-nicotinoylaminobenzoyl)-3-(3-cyclopentyloxy-4-  
methoxyphenyl)-1,4,5,6-tetrahydropyridazine,  
1-(3-nicotinoylaminobenzoyl)-3-(3-cyclopentyloxy-4-  
methoxyphenyl)-1,4,5,6-tetrahydropyridazine,  
10 1-(4-nicotinoylaminobenzoyl)-3-(3,4-methylene-dioxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
1-(4-nicotinoylaminobenzoyl)-3-(3-methoxy-4-  
methylsulfonylphenyl)-1,4,5,6-tetrahydro-pyridazine,  
15 1-(4-nicotinoylaminobenzoyl)-3-(3-trifluoro-methoxy-4-  
methoxyphenyl)-1,4,5,6-tetrahydro-pyridazine,  
1-(4-ethoxy-carbonylaminobenzoyl)-3-(3,4-dimethoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
20 1-(3-ethoxycarbonylaminobenzoyl)-3-(3,4-dimethoxy-phenyl)-  
1,4,5,6-tetrahydropyridazine,  
1-(2-ethoxycarbonylaminobenzoyl)-3-(3,4-dimethoxy-phenyl)-  
1,4,5,6-tetrahydropyridazine,  
25 1-(4-ethoxycarbonylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
1-(3-ethoxycarbonylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
30 1-(4-ethoxycarbonylaminobenzoyl)-3-(3-cyclo-pentyloxy-4-  
methoxyphenyl)-1,4,5,6-tetrahydro-pyridazine,  
1-(3-ethoxycarbonylaminobenzoyl)-3-(3-cyclo-pentyloxy-4-  
methoxyphenyl)-1,4,5,6-tetrahydro-pyridazine,  
1-(4-ethoxycarbonylaminobenzoyl)-3-(3,4-methylene-dioxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
35 1-(4-ethoxycarbonylaminobenzoyl)-3-(3-methoxy-4-  
methylsulfonylphenyl)-1,4,5,6-tetrahydro-pyridazine,

1-(4-ethoxycarbonylaminobenzoyl)-3-(3-trifluoro-methoxy-4-methoxyphenyl)-1,4,5,6-tetrahydro-pyridazine,  
and the stereoisomers and physiologically acceptable salts and solvates thereof;

5

e) compounds disclosed in EP 0723962

3-(4-ethoxycarbonylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,

10

3-(4-ethoxycarbonylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,  
and their physiologically acceptable salts and solvates;

15

f) compounds disclosed in EP 0738715

2-(4-butyrylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-acetamidobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

20

2-(4-trifluoroacetamidobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methylsulfonamidobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

25

2-(4-propionylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-tert-butylcarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

30

2-(4-isobutyrylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methoxycarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

35

2-(4-pivalylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-cyclopentylcarbonylbenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-ethoxycarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

5 2-(4-methoxalylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-ureidobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

10 2-(4-pentanoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-hexanoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

15 2-(4-pentafluoropropionylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-acetamidobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

20 2-(4-trifluoroacetamidobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methylsulfonamidobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

25 2-(4-propionylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-tert-butylcarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

30 2-(4-butyrylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-isobutyrylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

35 2-(4-methoxycarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-pivalylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

- 2-(4-cyclopentylcarbamoylbenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-  
2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-ethoxycarbonylaminobenzy)-6-(3,4-dimethoxyphenyl)-5-ethyl-  
2,3,4,5-tetrahydropyridazin-3-one,
- 5 2-(4-methoxalylaminobenzy)-6-(3,4-dimethoxyphenyl)-5-ethyl-  
2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-ureidobenzy)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetra-  
hydropyridazin-3-one,
- 10 2-(4-pentanoylaminobenzy)-6-(3,4-dimethoxyphenyl)-5-ethyl-  
2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-hexanoylaminobenzy)-6-(3,4-dimethoxyphenyl)-5-ethyl-  
2,3,4,5-tetrahydropyridazin-3-one,
- 15 2-(4-pentafluoropropionylaminobenzy)-6-(3,4-dimethoxyphenyl)-5-  
ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-acetamidobenzy)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-  
2,3,4,5-tetrahydropyridazin-3-one,
- 20 2-(4-trifluoroacetamidobenzy)-6-(3-ethoxy-4-methoxyphenyl)-5-  
ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-methylsulfonamidobenzy)-6-(3-ethoxy-4-methoxyphenyl)-5-  
ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 25 2-(4-propionylaminobenzy)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-  
2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-butyrylaminobenzy)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-  
2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-isobutyrylaminobenzy)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-  
2,3,4,5-tetrahydropyridazin-3-one,
- 30 2-(4-methoxycarbonylaminobenzy)-6-(3-ethoxy-4-methoxyphenyl)-  
5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-pivalylaminobenzy)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-  
2,3,4,5-tetrahydropyridazin-3-one,
- 35 2-(4-cyclopentylcarbamoylbenzy)-6-(3-ethoxy-4-methoxyphenyl)-5-  
ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-ethoxycarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one;

2-(4-methoxalylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

5 2-(4-ureidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-pentanoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

10 2-(4-hexanoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-pentafluoropropionylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

15 2-(4-acetamidobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-trifluoroacetamidobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

20 2-(4-methylsulfonamidobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-propionylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

25 2-(4-tert-butylcarbonylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-butyrylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

30 2-(4-isobutyrylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methoxycarbonylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-pivalylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

35 2-(4-cyclopentylcarbamoylbenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

- 2-(4-ethoxycarbonylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-methoxalylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 5 2-(4-ureidobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-pentanoylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 10 2-(4-hexanoylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-pentafluoropropionylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 15 2-(4-acetamidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-trifluoroacetamidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 20 2-(4-methylsulfonamidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-propionylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 25 2-(4-butyrylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-isobutyrylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 30 2-(4-methoxycarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-pivalylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 35 2-(4-cyclopentylcarbamoylbenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-ethoxycarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,



2-(4-methoxalaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,

2-(4-ureidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetra-  
hydropyridazin-3-one,

5 2-(4-pentanoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,

2-(4-hexanoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-  
tetrahydropyridazin-3-one,

10 2-(4-pentafluoropropionylaminobenzyl)-6-(3-ethoxy-4-methoxy-  
phenyl)-2,3,4,5-tetrahydropyridazin-3-one,

and their physiologically acceptable salts and solvates;

15 g) compounds disclosed in EP 0539806

5-(3-methoxy-4-difluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on, mp. 97°;

5-(3-methoxy-4-trifluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on;

20 5-(3-methoxy-4-trifluormethoxyphenyl)-6-methyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on;

5-(3-methoxy-4-difluormethoxyphenyl)-6-methyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on;

25 5-[3-methoxy-4-(1,1,2,2-tetrafluorethoxy)-phenyl]-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazin-2-on;

5-(3-methoxy-4-chlormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on;

30 5-(3-methoxy-4-chlormethoxyphenyl)-6-methyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on;

5-(3-methoxy-4-pentachlorethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on;

35 5-(3-methoxy-4-trifluormethoxyphenyl)-6-propyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on;

5-(3-methoxy-4-difluormethoxyphenyl)-6-propyl-3,6-dihydro-1,3,4-thiadiazin-2-on;

5-[3-methoxy-4-(1,1,2,-trifluorethoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on;

5 5-[3-methoxy-4-(1,1,2,-trifluorethoxy)-phenyl]-6-methyl-3,6-dihydro-1,3,4-thiadiazin-2-on;

5-(3-methoxy-4-difluormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on, mp. 120°;

10 5-(3-methoxy-4-trifluormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on;

5-(4-trifluormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on;

15 5-[3-methoxy-4-(1,1,2,2-tetrafluorethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on;

5-(3-methoxy-4-chlormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on;

5-(3-methoxy-4-trichlormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on;

20 5-(3-methoxy-4-pentachlorethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on;

5-(4-difluormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on;

25 5-[3-methoxy-4-(1,1,2,2,3-pentafluoropropoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on;

5-[bis-3,4-(difluormethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on;

30 5-[bis-3,4-(dichlormethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on;

5-[bis-3,4-(1,2-difluorethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on;

5-[3-ethoxy-4-(1,1,2,2,-tetrafluorethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on;

35 5-[3-methoxy-4-(1,2,2,-trichlorethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on;

5-[4-(2,2,2-trifluoroethoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on, mp. 102°;

5-[3-methoxy-4-(2,2,2-trifluoroethoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on, mp. 123-125°;

5 5-[3-methoxy-4-(2,2,2-trifluoroethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on, mp. 120°;

5-[3-(2,2,2-trifluoroethoxy)-4-methoxy-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on, mp. 120-121°;

10 5-(3-difluormethoxy-4-methoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on, mp. 105°;

and their physiologically acceptable salts and solvates;

15 h) compounds disclosed in EP 0618201

3-dimethylaminopropyl-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on, mp. 175°;

3-dimethylaminopropyl-5-(3-methoxy-4-trifluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

20 3-dimethylaminopropyl-5-(3-methoxy-4-difluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

3-dimethylaminopropyl-5-(3-methoxy-4-fluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

25 3-dimethylaminopropyl-5-(4-methoxy-3-difluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

3-dimethylaminopropyl-5-[4-methoxy-3-(2,2,2-trifluoroethoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

30 3-dimethylaminopropyl-5-(4-methoxy-3-fluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

3-dimethylaminopropyl-5-(3-methoxy-4-ethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

35 3-dimethylaminopropyl-5-(4-methoxy-3-ethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

- 3-dimethylaminopropyl-5-(3-methoxy-4-hydroxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 3-dimethylaminopropyl-5-(3,4-dimethoxy-phenyl)-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 5 2-dimethylaminoethyl-5-(3,4-dimethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 2-dimethylaminoethyl-5-(3-methoxy-4-trifluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 10 2-dimethylaminoethyl-5-(3-methoxy-4-difluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 2-dimethylaminoethyl-5-(3-methoxy-4-fluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 15 2-dimethylaminoethyl-5-(4-methoxy-3-difluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 2-dimethylaminoethyl-5-(4-methoxy-3-fluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 20 2-dimethylaminoethyl-5-(3-methoxy-4-ethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 2-dimethylaminoethyl-5-(4-methoxy-3-ethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 25 2-dimethylaminoethyl-5-(4-methoxy-3-hydroxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 3-morpholinopropyl-5-[3-methoxy-4-(1,1,2,2,3-pentafluoropropoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 3-dimethylaminopropyl-5-[3,4-bis-(difluormethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 30 3-dimethylaminopropyl-5-[3-methoxy-4-(1,1,2-trifluoroethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 3-dimethylaminopropyl-5-[3,4-bis-(chlormethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazinon-2-on;
- 35 3-morpholinopropyl-5-(3-methoxy-4-fluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

3-morpholinopropyl-5-(3-methoxy-4-trifluormethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazinon-2-on;

3-piperidinopropyl-5-(3-methoxy-4-difluormethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazinon-2-on;

5 3-morpholinopropyl-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-  
1,3,4-thiadiazinon-2-on;

3-piperidinopropyl-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-  
1,3,4-thiadiazinon-2-on;

10 3-pyrrolidinopropyl-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-  
1,3,4-thiadiazinon-2-on;

3-morpholinopropyl-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazinon-2-on;

15 3-piperidinopropyl-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazinon-2-on;

3-pyrrolidinopropyl-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazinon-2-on;

20 3-morpholinopropyl-5-(4-methoxy-3-ethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazinon-2-on;

3-piperidinopropyl-5-(4-methoxy-3-ethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazinon-2-on;

25 3-morpholinopropyl-5-(3-methoxy-4-difluormethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazinon-2-on;

3-piperidinopropyl-5-(4-methoxy-3-difluormethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazinon-2-on;

30 3-piperidinopropyl-5-[3-(2,2,2-trifluorethoxy)-4-methoxyphenyl]-6-  
ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

3-morpholinopropyl-5-[3-(2,2,2-trifluorethoxy)-4-methoxyphenyl]-6-  
ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on;

35 2-morpholinoethyl-5-(3-methoxy-4-fluormethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazinon-2-on;

2-morpholinoethyl-5-(3-methoxy-4-trifluormethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazinon-2-on;

and their physiologically acceptable salts and solvates;

for preparing a medicament for treating a subject suffering from a disease  
or condition mediated by the PDE4 isozyme in its role of regulating the  
activation and degranulation of human eosinophils.

Most preferably, the invention provides for the use of the following  
compounds

3-(4-nicotinoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-  
ylcarbonyl)phenyl)-4-methoxybenzoyl-3-carboxamide,

1-(4-nicotinoylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,

1-(4-ethoxycarbonylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,

2-(4-ethoxycarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,

and their physiologically acceptable salts and solvates;

for preparing a medicament for treating a subject suffering from a disease  
or condition mediated by the PDE4 isozyme in its role of regulating the  
activation and degranulation of human eosinophils.

The preferred compounds show a selective inhibition of phospho-  
diesterase IV, which is associated with an intracellular increase in cAMP  
(N. Sommer et al., Nature Medicine, **1**, 244-248 (1995)).

The inhibition of PDE IV can be demonstrated, for example, analogously to  
C.W. Davis in Biochim. Biophys. Acta **797**, 354-362 (1984).

The affinity of the compounds of the invention for phosphodiesterase IV is  
measured by determining their IC<sub>50</sub> values (the concentration of inhibitor  
required to achieve 50% inhibition of the enzyme activity).

5 WO 01/57025 discloses various in vitro assays and animal model experiments, which are capable of providing data sufficient to define and demonstrate the therapeutic utility of PDE IV inhibitors.

10 The preferred compounds inhibit the PDE4 isozyme and thereby have a wide range of therapeutic applications, because of the essential role which the PDE4 family of isozymes plays in the physiology of all mammals. The enzymatic role performed by the PDE4 isozymes is the intracellular hydrolysis of adenosine 3', 5'-monophosphate (cAMP) within pro-inflammatory leukocytes. cAMP, in turn, is responsible for mediating the effects of numerous hormones in the body, and as a consequence, PDE4 inhibition plays a significant role in a variety of physiological processes.

15 There is extensive literature in the art describing the effects of PDE inhibitors on various inflammatory cell responses, which in addition to cAMP elevation, include inhibition of superoxide production, degranulation, chemotaxis and tumor necrosis factor (TNF) release in eosinophils, neutrophils and monocytes.

20

25 Use of PDE IV inhibitors in treatment of asthma, inflammatory diseases, diabets mellitus, atopic dermatitis, psoriasis, AIDS, cancer, tumor growth and tumor metastases is disclosed in EP 779 291.

30 Preferably, the invention provides for the use of the preferred compounds mentioned above for preparing a medicament in treating or preventing one or members selected from the groups of diseases, disorders, and conditions consisting of:

35 asthma of whatever type, etiology, or pathogenesis; or asthma that is a member selected from the group consisting of atopic asthma; non-atopic asthma; allergic asthma; atopic, bronchial, IgE-mediated asthma; bronchial asthma; essential asthma; true asthma; intrinsic asthma caused by pathophysiologic disturbances; extrinsic asthma caused by environmental

factors; essential asthma of unknown or inapparent cause; non-atopic asthma; bronchitic asthma; emphysematous asthma; exercise-induced asthma; occupational asthma; infective asthma caused by bacterial, fungal, protozoal, or viral infection; non-allergic asthma; incipient asthma; wheezy infant syndrome;

chronic or acute bronchoconstriction; chronic bronchitis; small airways obstruction; and emphysema;

obstructive or inflammatory airways diseases of whatever type, etiology, or pathogenesis; or an obstructive or inflammatory airways disease that is a member selected from the group consisting of asthma; pneumoconiosis; chronic eosinophilic pneumonia; chronic obstructive pulmonary disease (COPD); COPD that includes chronic bronchitis, pulmonary emphysema or dyspnea associated therewith; COPD that is characterized by irreversible, progressive airways obstruction; adult respiratory distress syndrome (ARDS), and exacerbation of airways hyper-reactivity consequent to other drug therapy;

pneumoconiosis of whatever type, etiology, or pathogenesis; or pneumoconiosis that is a member selected from the group consisting of aluminosis or bauxite workers' disease; anthracosis or miners' asthma; asbestosis or steam-fitters' asthma; chalicosis or flint disease; ptilosis caused by inhaling the dust from ostrich feathers; siderosis caused by the inhalation of iron particles; silicosis or grinders' disease; byssinosis or cotton-dust asthma; and talc pneumoconiosis;

bronchitis of whatever type, etiology, or pathogenesis; or bronchitis that is a member selected from the group consisting of acute bronchitis; acute laryngotracheal bronchitis; arachidic bronchitis; catarrhal bronchitis; croupus bronchitis; dry bronchitis; infectious asthmatic bronchitis; productive bronchitis; staphylococcus or streptococcal bronchitis; and vesicular bronchitis;

bronchiectasis of whatever type, etiology, or pathogenesis; or bronchiectasis that is a member selected from the group consisting of cylindric bronchiectasis; sacculated bronchiectasis; fusiform



bronchiectasis; capillary bronchiectasis; cystic bronchiectasis; dry  
bronchiectasis; and follicular bronchiectasis;

5           seasonal allergic rhinitis; or perennial allergic rhinitis; or sinusitis of  
whatever type, etiology, or pathogenesis; or sinusitis that is a member  
selected from the group consisting of purulent or nonpurulent sinusitis;  
acute or chronic sinusitis; and ethmoid, frontal, maxillary, or sphenoid  
sinusitis,

10           rheumatoid arthritis of whatever type, etiology, or pathogenesis; or  
rheumatoid arthritis that is a member selected from the group consisting of  
acute arthritis; acute gouty arthritis; chronic inflammatory arthritis;  
degenerative arthritis; infectious arthritis; Lyme arthritis; proliferative  
arthritis; psoriatic arthritis; and vertebral arthritis;

15           gout, and fever and pain associated with inflammation;  
an eosinophil-related disorder of whatever type, etiology, or  
pathogenesis; or an eosinophil-related disorder that is a member  
selected from the group consisting of eosinophilia; pulmonary infiltration  
eosinophilia; Loffier's syndrome; chronic eosinophilic pneumonia; tropical  
20           pulmonary eosinophilia; bronchopneumonic aspergillosis; aspergilloma;  
granulomas containing eosinophils; allergic granulomatous angiitis 'or  
Churg-Strauss syndrome; polyarteritis nodosa (PAN); and systemic  
necrotizing vasculitis;

25           atopic dermatitis; or allergic dermatitis; or allergic or atopic eczema;  
urticaria of whatever type, etiology, or pathogenesis; or urticaria that  
is a member selected from the group consisting of immune-mediated  
urticaria; complement-mediated urticaria; urticariogenic material-induced  
urticaria; physical agent- induced urticaria; stressinduced urticaria;  
30           idiopathic urticaria; acute urticaria; chronic urticaria; angioedema;  
cholinergic urticaria; cold urticaria in the autosomal dominant form or in the  
acquired form; contact urticaria; giant urticaria; and papular urticaria;

35           conjunctivitis of whatever type, etiology, or pathogenesis; or  
conjunctivitis that is a member selected from the group consisting of actinic

conjunctivitis; acute catarrhal conjunctivitis; acute contagious conjunctivitis; allergic conjunctivitis; atopic conjunctivitis; chronic catarrhal conjunctivitis; purulent conjunctivitis; and vernal conjunctivitis;

5           uveitis of whatever type, etiology, or pathogenesis; or uveitis that is a member selected from the group consisting of inflammation of all or part of the uvea; anterior uveitis; iritis; cyclitis; iridocyclitis; granulomatous uveitis; nongranulomatous uveitis; phacoantigenic uveitis; posterior uveitis; choroiditis; and chorioretinitis;

10           psoriasis;

          multiple sclerosis of whatever type, etiology, or pathogenesis; or multiple sclerosis that is a member selected from the group consisting of primary progressive multiple sclerosis; and relapsing remitting multiple sclerosis;

15           autoimmune/inflammatory diseases of whatever type, etiology, or pathogenesis; or an autoimmune/inflammatory disease that is a member selected from the group consisting of autoimmune hematological disorders; hemolytic anemia; aplastic anemia; pure red cell anemia;

20           idiopathic thrombocytopenic purpura; systemic lupus erythematosus; polychondritis; scleroderma; Wegner's granulomatosis; dermatomyositis; chronic active hepatitis; myasthenia gravis; Stevens-Johnson syndrome; idiopathic sprue; autoimmune inflammatory bowel diseases; ulcerative

25           colitis; Crohn's disease; endocrin opthamopathy; Grave's disease; sarcoidosis; alveolitis; chronic hypersensitivity pneumonitis; primary biliary cirrhosis; juvenile diabetes or diabetes mellitus type 1; anterior uveitis; granulomatous or posterior uveitis; keratoconjunctivitis sicca; epidemic

30           keratoconjunctivitis; diffuse interstitial pulmonary fibrosis or interstitial lung fibrosis; idiopathic pulmonary fibrosis; cystic fibrosis; psoriatic arthritis; glomerulonephritis with and without nephrotic syndrome; acute glomerulonephritis; idiopathic nephrotic syndrome; minimal change nephropathy; inflammatory/ hyperproliferative skin diseases; psoriasis;

35           atopic dermatitis; contact dermatitis; allergic contact dermatitis; benign

familial pemphigus; pemphigus erythematosus; pemphigus foliaceus; and pemphigus vulgaris;

prevention of allogeneic graft rejection following organ transplantation;

5 inflammatory bowel disease (IBD) of whatever type, etiology, or pathogenesis; or inflammatory bowel disease that is a member selected from the group consisting of ulcerative colitis (UC); collagenous colitis; colitis polyposa; transmural colitis; and Crohn's disease (CD);

10 septic shock of whatever type, etiology, or pathogenesis; or septic shock that is a member selected from the group consisting of renal failure; acute renal failure; cachexia; malarial cachexia; hypophysial cachexia; uremic cachexia; cardiac cachexia; cachexia suprarenalis or Addison's disease; cancerous cachexia; and cachexia as a consequence of  
15 infection by the human immunodeficiency virus (HIV);

liver injury;

pulmonary hypertension; and hypoxia-induced pulmonary hypertension;

20 bone loss diseases; primary osteoporosis; and secondary osteoporosis;

central nervous system disorders of whatever type, etiology, or pathogenesis; or a central nervous system disorder that is a member  
25 selected from the group consisting of depression; Parkinson's disease; learning and memory impairment; tardive dyskinesia; drug dependence; arteriosclerotic dementia; and dementias that accompany Huntington's chorea, Wilson's disease, paralysis agitans, and thalamic atrophies;

30 infection, especially infection by viruses wherein such viruses increase the production of TNF- $\alpha$  in their host, or wherein such viruses are sensitive to upregulation of TNF- $\alpha$  in their host so that their replication or other vital activities are adversely impacted, including a virus which is a  
35 member selected from the group consisting of HIV-1, HIV-2, and HIV-3;

cytomegalovirus, CMV; influenza; adenoviruses; and Herpes viruses, including Herpes zoster and Herpes simplex;

yeast and fungus infections wherein said yeast and fungi are sensitive to upregulation by TNF- $\alpha$  or elicit TNF- $\alpha$  production in their host, e.g., fungal meningitis; particularly when administered in conjunction with other drugs of choice for the treatment of systemic yeast and fungus infections, including but are not limited to, polymyxins, e.g., Polymyxin B; imidazoles, e.g., clotrimazole, econazole, miconazole, and ketoconazole; triazoles, e.g., fluconazole and itraconazole; and amphotericins, e.g., Amphotericin B and liposomal Amphotericin B;

ischemia-reperfusion injury; autoimmune diabetes; retinal autoimmunity; chronic lymphocytic leukemia; HIV infections; lupus erythematosus; kidney and ureter disease; urogenital and gastrointestinal disorders; and prostate diseases.

In particular, the preferred compounds are useful in the treatment of (1) inflammatory diseases and conditions comprising: joint inflammation, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, inflammatory bowel disease, ulcerative colitis, chronic glomerulonephritis, dermatitis, and Crohn's disease; (2) respiratory diseases and conditions comprising: asthma, acute respiratory distress syndrome, chronic pulmonary inflammatory disease, bronchitis, chronic obstructive airway disease, and silicosis; (3) infectious diseases and conditions comprising: sepsis, septic shock, endotoxic shock, gram negative, sepsis, toxic shock syndrome, fever and myalgias due to bacterial, viral or fungal infection, and influenza; (4) immune diseases and conditions comprising: autoimmune diabetes, systemic lupus erythematosus, graft vs. host reaction, allograft rejections, multiple sclerosis, psoriasis, and allergic rhinitis; and (5) other diseases and conditions comprising: bone resorption diseases; reperfusion injury; cachexia secondary to infection or malignancy; cachexia secondary to human acquired immune deficiency syndrome (AIDS), human immuno-

deficiency virus (HIV) infection, or AIDS related complex (ARC); keloid formation; scar tissue formation; type 1 diabetes mellitus; and leukemia.

5 The present invention further relates to the combination of a preferred compound of Formula I mentioned above together with one or more members selected from the group consisting of the following:

(a) leukotriene biosynthesis inhibitors: 5-lipoxygenase (5-LO) inhibitors and 5-lipoxygenase activating protein (FLAP) antagonists selected from the

10 group consisting of zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-substituted) thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones;

the class of methoxytetrahydropyrans which includes Zeneca ZD-2138;

15 the compound SB-210661 and the class to which it belongs; the class of pyridinyl-substituted 2-cyanonaphthafene compounds to which L 739,010 belongs; the class of 2-cyanoquinoline compounds to which L-746,530 belongs; the classes of indole and quinoline compounds to which MK-591, MK-886, and BAY x 1005 belong; (b) receptor antagonists for leukotrienes

20 LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub> selected from the group consisting of the phenothiazin-3-one class of compounds to which L-651,392 belongs; the class of amidino compounds to which CGS-25019c belongs; the class of benzoxalamines to which ontazolast belongs; the class of benzenecarboximidamides to which BIIL 284/260 belongs; and the classes of

25 compounds to which zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195 belong; (c) PDE4 inhibitors; (d) 5-Lipoxygenase (5-1-0)

30 inhibitors; or 5-lipoxygenase activating protein (FLAP) antagonists; (e) dual inhibitors of 5-lipoxygenase (5-LO) and antagonists of platelet activating factor (PAF); (f) leukotriene antagonists (LTRAs) including antagonists of LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>; (g) antihistaminic H<sub>1</sub> receptor antagonists including cetirizine, loratadine, desloratadine, fexofenadine, astemizole,

35 azelastine, and chlorpheniramine; (h) gastroprotective H<sub>2</sub> receptor

antagonists; (i)  $\alpha_1$ - and  $\alpha_2$ -adrenoceptor agonist vasoconstrictor  
sympathomimetic agents administered orally or topically for decongestant  
use, including propyl hexedrine, phenylephrine, phenylpropanolamine,  
5 pseudoephedrine, naphazoline hydrochloride, oxymetazoline  
hydrochloride, tetrahydrozoline hydrochloride, xylometazoline  
hydrochloride, and ethylnorepinephrine hydrochloride; j)  $\alpha_1$ - and  $\alpha_2$ -  
adrenoceptor agonists in combination with inhibitors of 5-lipoxygenase (5-  
LO); (k) anticholinergic agents including ipratropium bromide; tiotropium  
10 bromide; oxitropium bromide; pirzepine; and telenzepine; (l)  $\beta_1$ - to  $\beta_4$   
adrenoceptor agonists including etaproterenol, isoproterenol, isoprenaline,  
albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline,  
bitolterol mesylate, and pirbuterol; (m) methylxanthanines including  
15 theophylline and aminophylline; (n) sodium cromoglycate; (o) muscarinic  
receptor (M1, M2, and M3) antagonists; (p) COX-1 inhibitors (NSAIDs);  
COX-2 selective inhibitors including rofecoxib; and nitric oxide NSAIDs; (q)  
insulin-like growth factor type I (IGF-1) mimetics; (r) ciclesonide; (s)  
inhaled glucocorticoids with reduced systemic side effects, including  
20 prednisone, prednisolone, flunisolide, triamcinolone acetone,  
beclomethasone dipropionate, budesonide, fluticasone propionate, and  
mometasone furoate; (t) tryptase inhibitors; (u) platelet activating factor  
(PAF) antagonists; (v) monoclonal antibodies active against endogenous  
25 inflammatory entities; (w) IPL 576; (x) antitumor necrosis factor (TNF $\alpha$ )  
agents including Etanercept, Infliximab, and D2E7; (y) DMARDs including  
Leflunomide; (z) TCR peptides; (aa) interleukin converting enzyme (ICE)  
inhibitors; (bb) IMPDH inhibitors; (cc) adhesion molecule inhibitors  
30 including VLA-4 antagonists; (dd) cathepsins; (ee) MAP kinase inhibitors;  
(ff) glucose-6 phosphate dehydrogenase inhibitors; (gg) kinin-131 - and B2  
-receptor antagonists; (hh) gold in the form of an aurothio group together  
with various hydrophilic groups; (ii) immunosuppressive agents, e.g.,  
35 cyclosporine, azathioprine, and methotrexate; (jj) anti-gout agents, e.g.,  
colchicine; (kk) xanthine oxidase inhibitors, e.g., allopurinol; (ll) uricosuric

agents, e.g., probenecid, sulfinpyrazone, and benzbromarone; (mm) antineoplastic agents, especially antimitotic drugs including the vinca alkaloids such as vinblastine and vincristine; (nn) growth hormone secretagogues; (oo) inhibitors of matrix metalloproteases (MMPs), i.e., the  
5 stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11); (pp) transforming growth factor (TGFP); (qq)  
10 platelet-derived growth factor (PDGF); (rr) fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (ss) granulocyte macrophage colony stimulating factor (GM-CSF); (tt) capsaicin; (uu) Tachykinin NK<sub>1</sub> and NK<sub>3</sub> receptor antagonists selected from the group consisting of NKP-608C; SB233412 (talnetant); and D-4418; and (vv) elastase inhibitors selected  
15 from the group consisting of UT-77 and ZD-0892.

The present invention relates to a combination of a preferred compound as described above together with one or more additional therapeutic agents  
20 to be co-administered to a patient to obtain some particularly desired therapeutic end result. The second, etc. therapeutic agent may also be one or more compounds as described above or one or more PDE4 inhibitors known in the art and described in detail herein. More typically,  
25 the second, etc. therapeutic agent will be selected from a different class of therapeutic agents. These selections are described in detail below.

As used herein, the terms co-administration", "co-administered", and "in combination with", referring to the preferred compounds as mentioned  
30 above and one or more other therapeutic agents, is intended to mean, and does refer to and include the following:

(a) simultaneous administration of such combination of compound(s) and therapeutic agent(s) to a patient in need of treatment, when such  
35 components are formulated together into a single dosage form which releases said components at substantially the same time to said patient;

- 39 -

(b) substantially simultaneous administration of such combination of compound(s) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are ingested at substantially the same time by said patient, whereupon said components are released at

substantially the same time to said patient;

(c) sequential administration of

such combination of compound(s) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated apart from each other into separate dosage forms which are ingested at consecutive times by said patient with a significant time interval between each ingestion, whereupon said components are released at substantially different times to said patient; and

(d) sequential administration of such combination of compound(s) and therapeutic agent(s) to a patient in need of treatment, when such components are formulated together into a single dosage form which releases said components in a controlled manner whereupon they are concurrently, consecutively, and/or overlappingly ingested at the same and/or different times by said patient.

Combinations with Leukotriene Biosynthesis Inhibitors: 5-Lipoxygenase (5-LO) Inhibitors and 5-Lipoxygenase Activating Protein (FLAP) Antagonists

One or more of the preferred compounds mentioned above is used in combination with leukotriene biosynthesis inhibitors, i.e., 5-lipoxygenase inhibitors and/or 5-lipoxygenase activating protein antagonists, to form embodiments of the present invention. 5-Lipoxygenase (5-LO) is one of two groups of enzymes that metabolize arachidonic acid, the other group being the cyclooxygenases, COX-1 and COX-2.

The 5-lipoxygenase activating protein is an 18 kDa membrane-bound, arachidonate-binding protein which stimulates the conversion of cellular



arachidonic acid by 5-lipoxygenase. The arachidonic acid is converted into 5-hydroperoxyeicosatetraenoic acid (5-HPETE), and this pathway eventually leads to the production of inflammatory leukotrienes; consequently, blocking the 5-lipoxygenase activating protein or the 5-lipoxygenase enzyme itself provides a desirable target for beneficially interfering with that pathway. One such 5-lipoxygenase inhibitor is zileuton. Among the classes of leukotriene synthesis inhibitors which are useful for forming therapeutic combinations with the preferred compounds

mentioned above are the following:


(a) redox-active agents which include N-hydroxyureas; N-alkylhydroxamid acids; selenite; hydroxybenzofurans; hydroxylamines; and catechols; see Ford- Hutchinson et al., "5-Lipoxygenase," *Ann. Rev. Biochem.* **63**, 383-417, 1994; Weitzel and Wendel, "Selenoenzymes regulate the activity of leukocyte 5-lipoxygenase via the peroxide tone," *J. Biol. Chem.* **268**, 6288-92, 1993; Björnstedt et al. "Selenite incubated with NADPH and mammalian thioredoxin reductase yields selenide, which inhibits lipoxygenase and changes the electron spin resonance spectrum of the active site iron," *Biochemistry* **35**, 8511-6, 1996; and Stewart et al., "Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors," *J. Med. Chem.* **40**, 1955-68, 1997;

(b) alkylating agents and compounds which react with SH groups have been found to inhibit leukotriene synthesis in vitro; see Larsson et al., "Effects of 1-chloro-2,4,6-trinitrobenzene on 5-lipoxygenase activity and cellular leukotriene synthesis," *Biochem. Pharmacol.* **55**, 863-71, 1998; and


(c) competitive inhibitors of 5-lipoxygenase, based on thiopyranoindole and methoxyalkyl thiazole structures which may act as non-redox inhibitors of 5-lipoxygenase; see Ford-Hutchinson et al., *Ibid.*; and Hamel et al., "Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-

lipoxygenase inhibitors - synthesis, biological profile, and pharmacokinetics of L-739,010," J. Med. Chem. **40**, 2866-75, 1997.

The observation that arachidonoyl hydroxyamate inhibits 5-lipoxygenase has led to the discovery of clinically useful selective 5-lipoxygenase inhibitors such as the N-hydroxyurea derivatives zileuton and ABT-761, represented below:




Zileuton ;



ABT-761


Another N-hydroxyurea compound is fenleuton (Abbott-76745):



Fenleuton.

Another N-hydroxyurea compound is Abbott-79175

- 42 -




Abbott-79175.

5

Abbott-79175 has a longer duration of action than zileuton;  
Brooks et al., J. Pharm. Exp. Therapeut 272 724, 1995.

10

A still further N-hydroxyurea compound is Abbott-85761



Abbott-85761.

15

Abbott-85761 is delivered to the lung by aerosol administration of a  
homogeneous, physically stable and nearly monodispersed formulation;  
Gupta et al., "Pulmonary delivery of the 5-lipoxygenase inhibitor, Abbott-  
85761, in beagle dogs," International Journal of Pharmaceutics **147**, 207-  
218, 1997.

20

Fenleuton, Abbott-79175, Abbott-85761 or any of the above-described  
derivatives thereof or of tepoxalin, are combined with the preferred  
compounds described above to form embodiments of the present  
invention.

25


Since the elucidation of the 5-LO biosynthetic pathway, there has been an  
ongoing debate as to whether it is more advantageous to inhibit the 5-  
lipoxygenase enzyme or to antagonize peptido- or non-peptido leukotriene  
receptors. Inhibitors of 5-lipoxygenase are deemed to be superior to LT-

30


35

- 43 -

receptor antagonists, since 5-lipoxygenase inhibitors block the action of the full spectrum of 5-LO products, whereas LT-antagonists produce narrower effects. Nevertheless, embodiments of the present invention include combinations of the preferred compounds with LT-antagonists as well as 5-LO inhibitors, as described below. Inhibitors of 5-lipoxygenase having chemical structures that differ from the classes of N-hydroxyureas and hydroxamic acids described above are also used in combination with the preferred compounds to form further embodiments of the present invention. An example of such a different class is the N-(5-substituted)-thiophene-2-alkylsulfonamides of following formula




where X is O or S; R' is methyl, iso-propyl, n-butyl, n-octyl, or phenyl; and R is n-pentyl, cyclohexyl, phenyl, tetrahydro-1-naphthyl, 1- or 2-naphthyl, or phenyl mono- or di-substituted by Cl, F, Br, CH<sub>3</sub>, OCH<sub>3</sub>, SCH<sub>3</sub>, SO<sub>2</sub>CH<sub>3</sub>, CF<sub>3</sub>, or iso-propyl. A preferred compound is



A further description of these compounds may be found in Beers et al., "N-(5-substituted) thiophene-2-alkylsulfonamides as potent inhibitors of 5-lipoxygenase," *Bioorganic & Medicinal Chemistry* 5(4), 779-786, 1997.

Another distinct class of 5-lipoxygenase inhibitors is that of the 2,6-di-tert-butylphenol hydrazones described in Cuadro et al., "Synthesis and


biological evaluation of 2,6-di-tert.-butylphenol hydrazones as 5-lipoxygenase inhibitors," *Bioorganic & Medicinal Chemistry* **6**, 173-180, 1998. Compounds of this type are represented by



15 where "Het" is benzoxazol-2-yl; benzothiazol-2-yl; pyridin-2-yl; pyrazin-2-yl; pyrimidin-2-yl; 4-phenylpyrimidin-2-yl; 4,6-diphenylpyrimidin-2-yl; 4-methylpyrimidin-2-yl; 4,6-dimethylpyrimidin-2-yl; 4-butylpyrimidin-2-yl; 4,6-dibutylpyrimidin-2-yl; and 4-methyl-6-phenylpyrimidin-2-yl.

20 The N-(5-substituted)-thiophene-2-alkylsulfonamides or the 2,6-di-tert-butylphenol hydrazones or any of the above-described derivatives thereof, are combined with the preferred compounds mentioned above to form embodiments of the present invention.

25 A further distinct class of 5-lipoxygenase inhibitors is that of methoxytetrahydropyrans to which Zeneca ZD-2138 belongs




ZD-2138.


- 45 -

ZD-2138 is highly selective and highly active orally in a number of species and has been evaluated in the treatment of asthma and rheumatoid arthritis by oral administration. Further details concerning ZD-2138 and derivatives thereof are disclosed in Crawley et al., J. Med. Chem., **35**, 2600, 1992; and Crawley et al., J. Med. Chem. **36**, 295, 1993.

Another distinct class of 5-lipoxygenase inhibitors is that to which the SmithKline Beecham compound SB-210661 belongs




Two further distinct and related classes of 5-lipoxygenase inhibitors comprise a series of pyridinyl-substituted 2-cyanonaphthalene compounds and a series of 2-cyanoquinoline compounds discovered by Merck Frosst. These two classes of 5-lipoxygenase inhibitors are exemplified by L-739,010 and L-746,530, respectively:



L-739,010

- 46 -



10 Details concerning L-739,010 and L-746,530 are disclosed in Dubé et al.,  
"Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological  
profile of L-746,530," *Bioorganic & Medicinal Chemistry* **8**, 1255-1260,  
1998; and in WO 95/03309 (Friesen et al.).


15 The class of methoxytetrahydropyrans including Zeneca ZD-2138; or the  
lead compound SB-210661 and the class to which it belongs; or the series  
of pyridinyl-substituted 2-cyanonaphthalene compounds to which L  
20 739,010 belongs, or the series of 2-cyanoquinoline compounds to which L-  
746,530 belongs; or any of the above-described derivatives of any of the  
above-mentioned classes, are combined with the preferred compounds  
mentioned above to form embodiments of the present invention.

25 In addition to the 5-lipoxygenase enzyme, the other endogenous agent  
which plays a significant role in the biosynthesis of the leukotrienes is the  
5-lipoxygenase activating protein (FLAP). This role is an indirect one, in  
contrast to the direct role of the 5-lipoxygenase enzyme. Nevertheless,  
30 antagonists of the 5-lipoxygenase activating protein are employed  
to inhibit the cellular synthesis of leukotrienes, and as such are also used  
in  
combination with the preferred compounds mentioned above to form  
35 embodiments of the present invention.

- 47 -

Compounds which bind to the 5-lipoxygenase activating protein and thereby block utilization of the endogenous pool of arachidonic acid which is present have been synthesized from indole and quinoline structures; see Ford-Hutchinson et al., *Ibid.*; Rouzer et al. "WK-886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes," *J. Biol. Chem.* **265**, 1436- 42, 1990; and Gorenne et al., "{(R)-2-quinolin-2-yl-methoxy)phenyl)-2-cyclopentyl acetic acid} (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways," *J. Pharmacol. Exp. Ther.* **268**, 868-72, 1994.

MK-591, which has been designated quiflipon sodium, is represented below




The above-mentioned indole and quinoline classes of compounds and the specific compounds MK-591, IVIK-886, and BAY x 1005 to which they belong, or any of the above-described derivatives of any of the above-mentioned classes, are combined with the preferred compounds mentioned above to form embodiments of the present invention.

Combinations with Receptor Antagonists for Leukotrienes  $LTB_4$ ,  $LTC_4$ ,  $LTD_4$ , and  $LTE_4$




One or more preferred compounds is used in combination with receptor antagonists for leukotrienes LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>. The most significant of these leukotrienes in terms of mediating inflammatory response, are LTB<sub>4</sub> and LTD<sub>4</sub>. Classes of antagonists for the receptors of these leukotrienes are described in the paragraphs which follow.

4-Bromo-2,7-dimethoxy-3H-phenothiazin-3-ones, including L-651,392, are potent receptor antagonists for LTB<sub>4</sub> that are described in US 4,939,145 (Guindon et al.) and US 4,845,083 (Lau et al.)



L-651,392.


A class of amidino compounds that includes CGS-25019c is described in US 5,451,700 (Morrissey and Suh); US 5,488,160 (Morrissey); and US 5,639,768 (Morrissey and Suh). These receptor antagonists for LTB<sub>4</sub> are typified by CGS-25019c, which is represented below:



CGS-25019c

Ontazolast, a member of a class of benzoxalamines that are receptor antagonists for LTB<sub>4</sub>, is described in EP 535 521 (Anderskewitz et A):

- 49 -




Ontozolast.

5

10

The same group of workers has also discovered a class of benzenecarb-oximidamides which are receptor antagonists for  $\text{LTB}_4$ , described in WO 97/21670 (Anderskewitz et al.); and WO 98/11119 (Anderskewitz et al.); and which are typified by BIIL 284/260:



15

20

BIIL 284/260


25

Zafirlukast is a receptor antagonist for  $\text{LTC}_4$ ,  $\text{LTD}_4$ , and  $\text{LTE}_4$  which is sold commercially under the name Accolate<sup>®</sup>. It belongs to a class of heterocyclic amide derivatives described in US 4,859,692 (Bernstein et al.); US 5,319,097 (Holohan and Edwards); US 5,294,636 (Edwards and Sherwood); US 5,482,963; US 5,583,152 (Bernstein et al.); and US 5,612,367 (Timko et al.):

30


35

- 50 -




Zafirlukast

10 Ablukast is a receptor antagonist for LTD<sub>4</sub> that is designated Ro 23-3544/001:



Ablukast

20 Montelukast is a receptor antagonist for LTD<sub>4</sub> which is sold commercially under the name Singulair<sup>®</sup> and is described in US 5,565,473:



Montekulast

35 Other receptor antagonists for LTD<sub>4</sub> include pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.

5 The above-mentioned phenothiazin-3-one class of compounds, including L- 651,392; the class of amidino compounds that includes CGS-25019c; the class of benzoxazolamines which includes Ontazolast; the class of benzenecarboximidamides which is typified by BIIL 284/260; the hetero-  
cyclic amide derivatives including Zafirlukast; Ablukast and Montelukast  
and the classes of compounds to which they belong; or any of the above-  
described derivatives of any of the above-mentioned classes, are  
combined with the preferred compounds to form embodiments of the  
10 present invention.

#### Combinations with other therapeutic agents

15 One or more preferred compounds are used together with other therapeutic agents as well as non-therapeutic agents to form combinations that are further embodiments of the present invention and that are useful in the  
treatment of a significant number of different diseases, disorders, and  
20 conditions described herein. Said embodiments comprise one or more preferred compounds together with one or more of the following:

- (a) PDE4 inhibitors;
- 25 (b) 5-Lipoxygenase (5-LO) inhibitors; or 5-lipoxygenase activating protein (FLAP) antagonists;
- (c) Dual inhibitors of 5-lipoxygenase (5-LO) and antagonists  
30 of platelet activating factor (PAF);
- (d) Leukotriene antagonists (LTRAs) including antagonists of LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>;
- (e) Antihistaminic H<sub>1</sub> receptor antagonists including cetirizine,  
loratadine, desloratadine, fexofenadine, astemizole, azelastine,  
35 and chlorpheniramine;
- (f) Gastroprotective H<sub>2</sub> receptor antagonists;

- 5 (g)  $\alpha_1$ - and  $\alpha_2$ -adrenoceptor agonist vasoconstrictor sympathomimetic agents administered orally or topically for decongestant use, including propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride;
- 10 (h)  $\alpha_1$ - and  $\alpha_2$ -adrenoceptor agonists in combination with inhibitors of 5-lipoxygenase (5-LO);
- (i) Anticholinergic agents including ipratropium bromide; tiotropium bromide; oxitropium bromide; pirenzepine; and telenzepine;
- 15 (j)  $\beta_1$ - to  $\beta_4$ -adrenoceptor agonists including metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol;
- (k) Theophylline and aminophylline;
- 20 (l) Sodium cromoglycate;
- (m) Muscarinic receptor (M1, M2, and M3) antagonists;
- (n) COX-1 inhibitors (NSAIDs); COX-2 selective inhibitors including rofecoxib; and nitric oxide NSAIDs;
- 25 (o) Insulin-like growth factor type I (IGF-1) mimetics;
- (p) Ciclesonide;
- (q) Inhaled glucocorticoids with reduced systemic side effects, including prednisone, prednisolone, flunisolide, triamcinolone acetone, beclomethasone dipropionate, budesonide, fluticasone propionate, and mometasone furoate;
- 30 (r) Tryptase inhibitors;
- (s) Platelet activating factor (PAF) antagonists;
- (t) Monoclonal antibodies active against endogenous inflammatory entities;
- 35 (u) IPL 576;

- 5 (v) Anti-tumor necrosis factor (TNF $\alpha$ ) agents including Etanercept, Infliximab, and D2E7;
- (w) DMARDs including Leflunomide;
- (x) TCR peptides;
- 5 (y) Interleukin converting enzyme (ICE) inhibitors;
- (z) IMPDH inhibitors;
- (aa) Adhesion molecule inhibitors including VLA-4 antagonists;
- (bb) Cathepsins;
- 10 (cc) MAP kinase inhibitors;
- (dd) Glucose-6 phosphate dehydrogenase inhibitors;
- (ee) Kinin-B<sub>1</sub>- and B<sub>2</sub>-receptor antagonists;
- (ff) Gold in the form of an aurothio group together with various hydrophilic groups;
- 15 (gg) Immunosuppressive agents, e.g., cyclosporine, azathioprine, and methotrexate;
- (hh) Anti-gout agents, e.g., colchicine;
- (ii) Xanthine oxidase inhibitors, e.g., allopurinol;
- 20 (jj) Uricosuric agents, e.g., probenecid, sulfinpyrazone, and benzbromarone;
- (kk) Antineoplastic agents, especially antimitotic drugs including the vinca alkaloids such as vinblastine and vincristine;
- 25 (ll) Growth hormone secretagogues;
- (mm) Inhibitors of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11);
- 30 (nn) Transforming growth factor (TGF $\beta$ );
- (oo) Platelet-derived growth factor (PDGF);
- 35 (pp) Fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF);

- (qq) Granulocyte macrophage colony stimulating factor (GM-CSF);  
(rr) Capsaicin;  
(ss) Tachykinin NK<sub>1</sub> and NK<sub>3</sub> receptor antagonists selected from the  
5 group consisting of NKP-608C; SB-233412 (talnetant); and D-  
4418;  
(tt) Elastase inhibitors selected from the group consisting of UT-77  
and ZD-0892; and  
(uu) Adenosine A2a receptor agonists.

#### Pharmaceutical Compositions and Formulations

15 The description which follows concerns the manner in which the  
preferred compounds as defined above or as defined in claims 1, 2 or 3,  
together with other therapeutic agents or non-therapeutic agents where  
these are desired, are combined with what are for the most part  
conventional pharmaceutically acceptable carriers to form dosage forms  
suitable for the different routes of administration which are utilized for any  
20 given patient, as well as appropriate to the disease, disorder, or condition  
for which any given patient is being treated.

25 The pharmaceutical compositions of the present invention comprise any  
one or more of the above-described inhibitory compounds of the present  
invention, or a pharmaceutically acceptable salt thereof as also above-  
described, together with a pharmaceutically acceptable carrier in  
accordance with the properties and expected performance of such carriers  
which are well-known in the pertinent art.

30  
35 The amount of active ingredient that may be combined with the carrier  
materials to produce a single dosage form will vary depending upon the  
host treated, and the particular mode of administration. It should be  
understood, however, that a specific dosage and treatment regimen for  
any particular patient will depend upon a variety of factors, including the

activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredient may also.

depend upon the therapeutic or prophylactic agent, if any, with which the ingredient is co-administered.

10 The preferred compounds may be utilized in the form of acids, esters, or other chemical classes of compounds to which the compounds described belong. It is also within the scope of the present invention to utilize those compounds in the form of pharmaceutically acceptable salts derived from various organic and inorganic acids and bases. An active ingredient 15 comprising a preferred compound is often utilized in the form of a salt thereof, especially where said salt form confers on said active ingredient improved pharmacokinetic properties as compared to the free form of said active ingredient or some other salt form of said active ingredient utilized 20 previously. The pharmaceutically acceptable salt form of said active ingredient may also initially confer a desirable pharmacokinetic property on said active ingredient which it did not previously possess, and may even positively affect the pharmacodynamics of said active ingredient with 25 respect to its therapeutic activity in the body.

The pharmacokinetic properties of said active ingredient which may be favorably affected include, e.g., the manner in which said active ingredient 30 is transported across cell membranes, which in turn may directly and positively affect the absorption, distribution, biotransformation and excretion of said active ingredient. While the route of administration of the pharmaceutical composition is important, and various anatomical, physiological and pathological factors can critically affect bioavailability, the 35 solubility of said active ingredient is usually dependent upon the character of the particular salt form thereof which it utilized. Further, as the artisan



understands, an aqueous solution of said active ingredient will provide the most rapid absorption of said active ingredient into the body of a patient being treated, while lipid solutions and suspensions, as well as solid dosage forms, will result in less rapid absorption of said active ingredient.

5 Oral ingestion of said active ingredient is the most preferred route of administration for reasons of safety, convenience, and economy, but absorption of such an oral dosage form can be adversely affected by physical characteristics such as polarity, emesis caused by irritation of the  
10 gastrointestinal mucosa, destruction by digestive enzymes and low pH, irregular absorption or propulsion in the presence of food or other drugs, and metabolism by enzymes of the mucosa, the intestinal flora, or the liver. Formulation of said active ingredient into different pharmaceutically acceptable salt forms may be effective in overcoming or alleviating one or  
15 more of the above- recited problems encountered with absorption of oral dosage forms.

20 Among the pharmaceutical salts recited further above, those which are preferred include, but are not limited to acetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate,  
25 tosylate, and tromethamine.

Multiple salts forms are included within the scope of the present invention where a preferred compound of the present invention contains more than one group capable of forming such pharmaceutically acceptable salts.

30 Examples of typical multiple salt forms include, but are not limited to bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium, and trihydrochloride.

35 The pharmaceutical compositions of the present invention comprise any one or more of the above-described inhibitory compounds as defined in

claims 1, 2 or 3, or a pharmaceutically acceptable salt thereof as also above-described, together with a pharmaceutically acceptable carrier in accordance with the properties and expected performance of such carriers which are well-known in the pertinent art.

5

The term "carrier" as used herein includes acceptable diluents, excipients, adjuvants, vehicles, solubilization aids, viscosity modifiers, preservatives and other agents well known to the artisan for providing favorable properties in the final pharmaceutical composition. In order to illustrate such carriers, there follows a brief survey of pharmaceutically acceptable carriers that may be used in the pharmaceutical compositions of the present invention, and thereafter a more detailed description of the various types of ingredients. Typical carriers include but are by no means limited to, ion exchange compositions; alumina; aluminum stearate; lecithin; serum proteins, e.g., human serum albumin; phosphates; glycine; sorbic acid; potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; hydrogenated palm oils; water; salts or electrolytes, e.g., prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts; colloidal silica; magnesium trisilicate; polyvinyl pyrrolidone; cellulose-based substances; e.g., sodium carboxymethylcellulose; polyethylene glycol; polyacrylates; waxes; polyethylene-polyoxypropylene-block polymers; and wool fat.

10

15

20

25

More particularly, the carriers used in the pharmaceutical compositions of the present invention comprise various classes and species of additives which are members independently selected from the groups consisting essentially of those recited in the following paragraphs.

30

Acidifying and alkalizing agents are added to obtain a desired or predetermined pH and comprise acidifying agents, e.g., acetic acid, glacial acetic acid, malic acid, and propionic acid. Stronger acids such as hydrochloric acid, nitric acid and sulfuric acid may be used but are

35

less preferred. Alkalizing agents include, e.g., edetol, potassium carbonate,  
potassium hydroxide, sodium borate, sodium carbonate, and sodium hydroxide. Alkalizing agents which contain active amine groups, such as  
5 diethanolamine and triethylamine, may also be used.

Aerosol propellants are required where the pharmaceutical composition is to be delivered as an aerosol under significant pressure. Such propellants  
10 include, e.g., acceptable fluorochlorohydrocarbons such as dichlorodifluoromethane, dichlorotetrafluoroethane, and trichloromonofluoromethane; nitrogen; or a volatile hydrocarbon such as butane, propane, isobutane or mixtures thereof.

15 Antimicrobial agents including antibacterial, antifungal and antiprotozoal agents are added where the pharmaceutical composition is topically applied to areas of the skin which are likely to have suffered adverse conditions or sustained abrasions or cuts which expose the skin to  
20 infection by bacteria, fungi or protozoa. Antimicrobial agents include such compounds as benzyl alcohol, chlorobutanol, phenylethyl alcohol, phenylmercuric acetate, potassium sorbate, and sorbic acid. Antifungal agents include such compounds as benzoic acid, butylparaben, ethylparaben,  
25 methylparaben, propylparaben, and sodium benzoate.

Antimicrobial preservatives are added to the pharmaceutical compositions of the present invention in order to protect them against the growth of  
30 potentially harmful microorganisms, which usually invade the aqueous phase, but in some cases can also grow in the oil phase of a composition. Thus, preservatives with both aqueous and lipid solubility are desirable. Suitable antimicrobial preservatives include, e.g., alkyl esters of p-  
35 hydroxybenzoic acid, propionate salts, phenoxyethanol, methylparaben sodium, propylparaben sodium, sodium dehydroacetate, benzalkonium chloride, benzethonium chloride, benzyl alcohol, hydantoin derivatives,

quaternary ammonium compounds and cationic polymers, imidazolidinyl urea, diazolidinyl urea, and trisodium ethylenediamine tetracetate (EDTA). Preservatives, are preferably employed in amounts ranging from about 0.01 % to about 2.0% by weight of the total composition.

5

Antioxidants are added to protect all of the ingredients of the pharmaceutical composition from damage or degradation by oxidizing agents present in the composition itself or the use environment, e.g., anoxomer, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, potassium metabisulfite, propyl octyl and dodecyl gallate, sodium metabisulfite, sulfur dioxide, and tocopherols.

10

Buffering agents are used to maintain a desired pH of a composition once established, from the effects of outside agents and shifting equilibria of components of the composition. The buffering may be selected from among those familiar to the artisan skilled in the preparation of pharmaceutical compositions, e. g., calcium, acetate, potassium metaphosphate, potassium phosphate monobasic, and tartaric acid.

15

20

Chelating agents are used to help maintain the ionic strength of the pharmaceutical composition and bind to and effectively remove destructive compounds and metals, and include, e.g., edetate dipotassium, edetate disodium, and edetic acid.

25

Dermatologically active agents are added to the pharmaceutical compositions of the present invention where they are to be applied topically, and include, e.g., wound healing agents such as peptide derivatives, yeast, panthenol, hexylresorcinol, phenol, tetracycline hydrochloride, lamin and kinetin; retinoids for treating skin cancer, e.g., retinol, tretinoin, isotretinoin, etretinate, acitretin, and arotinoid; mild antibacterial agents for treating skin infections, e.g., resorcinol, salicylic acid, benzoyl peroxide, erythromycin-benzoyl peroxide, erythromycin, and clindamycin;

30

35

antifungal agents for treating tinea corporis, tinea pedis, candidiasis and tinea versicolor, e.g., griseofulvin, azoles such as miconazole, econazole, itraconazole, fluconazole, and ketoconazole, and allylamines such as naftifine and terfenadine; antiviral agents for treating cutaneous herpes simplex, herpes zoster, and chickenpox, e.g., acyclovir, famciclovir, and valacyclovir; antihistamines for treating pruritis, atopic and contact dermatitis, e.g., diphenhydramine, terfenadine, astemizole, loratadine, cetirizine, acrivastine, and temelastine; topical anesthetics for relieving pain, irritation and itching, e.g., benzocaine, lidocaine, dibucaine, and pramoxine hydrochloride; topical analgesics for relieving pain and inflammation, e.g., methyl salicylate, camphor, menthol, and resorcinol; topical antiseptics for preventing infection, e.g., benzalkonium chloride and povidone-iodine; and vitamins and derivatives thereof such as tocopherol, tocopherol acetate, retinoic acid and retinol.

Dispersing and suspending agents are used as aids for the preparation of stable formulations and include, e.g., poligeenan, povidone, and silicon dioxide.

Emollients are agents, preferably non-oily and water-soluble, which soften and soothe the skin, especially skin that has become dry because of excessive loss of water. Such agents are used with pharmaceutical compositions of the present invention which are intended for topical applications, and include, e.g., hydrocarbon oils and waxes, triglyceride esters, acetylated monoglycerides, methyl and other alkyl esters of  $C_{10}$  -  $C_{20}$  fatty acids,  $C_{10}$  -  $C_{20}$  fatty acids,  $C_{10}$  -  $C_{20}$  fatty alcohols, lanolin and derivatives, polyhydric alcohol esters such as polyethylene glycol (200-600), polyoxyethylene sorbitan fatty acid esters, wax esters, phospholipids, and sterols; emulsifying agents used for preparing oil-in-water emulsions; excipients, e.g., laurocapram and polyethylene glycol monomethyl ether; humectants, e.g., sorbitol, glycerin and hyaluronic acid; ointment bases, e.g., petrolatum, polyethylene glycol, lanolin, and poloxamer; penetration

enhancers, e.g., dimethyl isosorbide, diethyl-glycol monoethylether, 1-dodecylazacycloheptan-2-one, and dimethylsulfoxide (DMSO); preservatives, e.g., benzalkonium chloride, benzethonium chloride, alkyl esters of p hydroxybenzoic acid, hydantoin derivatives, cetylpyridinium chloride, propylparaben, quaternary ammonium compounds such as potassium benzoate, and thimerosal; sequestering agents comprising cyclodextrins; solvents, e.g., acetone, alcohol, amylene hydrate, butyl alcohol, corn oil, cottonseed oil, ethyl acetate, glycerin, hexylene glycol, isopropyl alcohol, isostearyl alcohol, methyl alcohol, methylene chloride, mineral oil, peanut oil, phosphoric acid, polyethylene glycol, polyoxypropylene 15 stearyl ether, propylene glycol, propylene glycol diacetate, sesame oil, and purified water; stabilizers, e.g., calcium saccharate and thymol; surfactants, e.g., lauryl chloride; laureth 4, ie.,  $\alpha$ -dodecyl- $\omega$ -hydroxy-poly(oxy-1,2-ethanediyl) or polyethylene glycol monododecyl ether.

Emulsifying agents, including emulsifying and stiffening agents and emulsion adjuncts, are used for preparing oil-in-water emulsions when these form the basis of the pharmaceutical compositions of the present invention. Such emulsifying agents include, e.g., non-ionic emulsifiers such as C<sub>10</sub> -C<sub>20</sub> fatty alcohols and said fatty alcohols condensed with from 2 to 20 moles of ethylene oxide or propylene oxide, (C<sub>6</sub> -C<sub>12</sub>)alkyl phenols condensed with from 2 to 20 moles of ethylene oxide, mono- and di-C<sub>10</sub> -C<sub>20</sub> fatty acid esters of ethylene glycol, C<sub>10</sub> -C<sub>20</sub> fatty acid monoglyceride, diethylene glycol, polyethylene glycols of MW 200 6000, polypropylene glycols of MW 200-3000, and particularly sorbitol, sorbitan, polyoxyethylene sorbitol, polyoxyethylene sorbitan, hydrophilic wax esters, cetostearyl alcohol, oleyl alcohol, lanolin alcohols, cholesterol, mono- and di-glycerides, glyceryl monostearate, polyethylene glycol monostearate, mixed mono- and distearic esters of ethylene glycol and polyoxyethylene glycol, propylene glycol monostearate, and hydroxypropyl cellulose.

Emulsifying agents which contain active amine groups may also be used and typically include anionic emulsifiers such as fatty acid soaps, e.g., sodium, potassium and triethanolamine soaps of C<sub>10</sub> -C<sub>20</sub> fatty acids; alkali metal, ammonium or substituted ammonium (C<sub>10</sub> -C<sub>30</sub>)alkyl sulfates, (C<sub>10</sub> -C<sub>30</sub>)alkyl sulfonates, and (C<sub>10</sub> -C<sub>50</sub>)alkyl ethoxy ether sulfonates. Other suitable emulsifying agents include castor oil and hydrogenated castor oil; lecithin; and polymers of 2-propenoic acid together with polymers of acrylic acid, both cross-linked with allyl ethers of sucrose and/or pentaerythritol, having varying viscosities and identified by product names carbomer 910, 934, 934P, 940, 941, and 1342. Cationic emulsifiers having active amine groups may also be used, including those based on quaternary ammonium, morpholinium and pyridinium compounds. Similarly, amphoteric emulsifiers having active amine groups, such as cocobetaines, lauryl dimethylamine oxide and cocoylimidazoline, may be used. Useful emulsifying and stiffening agents also include cetyl alcohol and sodium stearate; and emulsion adjuncts such as oleic acid, stearic acid, and stearyl alcohol.

Excipients include, e.g., laurocapram and polyethylene glycol monomethyl ether.

Where the pharmaceutical composition of the present invention is to be applied topically, penetration enhancers may be used, which include, e.g., dimethyl isosorbide, diethyl-glycol-monoethylether, 1-dodecylazacycloheptan-2-one, and dimethylsulfoxide (DMSO). Such compositions will also typically include ointment bases, e.g., petrolatum, polyethylene glycol, lanolin, and poloxamer, which is a block copolymer of polyoxyethylene and polyoxypropylene, which may also serve as a surfactant or emulsifying agent.

Preservatives are used to protect pharmaceutical compositions of the present invention from degradative attack by ambient microorganisms, and include, e.g., benzalkonium chloride, benzethonium chloride, alkyl esters of

5 p-hydroxybenzoic acid, hydantoin derivatives, cetylpyridinium chloride, monothioglycerol, phenol, phenoxyethanol, methylparagen, imidazolidinyl urea, sodium dehydroacetate, propylparaben, quaternary ammonium compounds, especially polymers such as polixetonium chloride, potassium benzoate, sodium formaldehyde sulfoxylate, sodium propionate, and thimerosal.

10 Sequestering agents are used to improve the stability of the pharmaceutical compositions of the present invention and include, e.g., the cyclodextrins which are a family of natural cyclic oligosaccharides capable of forming inclusion complexes with a variety of materials, and are of varying ring sizes, those having 6-, 7- and 8-glucose residues in a ring being  
15 commonly referred to as  $\alpha$ -cyclodextrins,  $\beta$ -cyclodextrins, and  $\gamma$ -cyclodextrins, respectively. Suitable cyclodextrins include, e.g.,  $\alpha$ -cyclodextrin,  $\beta$ -cyclodextrin,  $\gamma$ -cyclodextrin,  $\delta$ -cyclodextrin and cationized cyclodextrins.

20 Solvents which may be used in preparing the pharmaceutical compositions of the present invention include, e.g., acetone, alcohol, amylene hydrate, butyl alcohol, corn oil, cottonseed oil, ethyl acetate, glycerin, hexylene glycol, isopropyl alcohol, isostearyl alcohol, methyl alcohol, methylene chloride, mineral oil, peanut oil, phosphoric acid, polyethylene glycol,  
25 polyoxypropylene 15 stearyl ether, propylene glycol, propylene glycol diacetate, sesame oil, and purified water.

30 Stabilizers which are suitable for use include, e.g., calcium saccharate and thymol.

Stiffening agents are typically used in formulations for topical applications in order to provide desired viscosity and handling characteristics and include, e.g., cetyl esters wax, myristyl alcohol, parafin, synthetic parafin,  
35 emulsifying wax, microcrystalline wax, white wax and yellow wax.



Sugars are often used to impart a variety of desired characteristics to the pharmaceutical compositions of the present invention and in order to improve the results obtained, and include, e.g., monosaccharides, disaccharides and polysaccharides such as glucose, xylose, fructose, reose, ribose, pentose, arabinose, allose, tallose, altrose, mannose, galactose, lactose, sucrose, erythrose, glyceraldehyde, or any combination thereof.

Surfactants are employed to provide stability for multi-component pharmaceutical compositions of the present invention, enhance existing properties of those compositions, and bestow desirable new characteristics on said compositions. Surfactants are used as wetting agents, antifoam agents, for reducing the surface tension of water, and as emulsifiers, dispersing agents and penetrants, and include, e.g., lapyrium chloride; laureth 4, i.e.,  $\alpha$ -dodecyl- $\omega$ -hydroxy-poly(oxy-1,2-ethanediyl) or polyethylene glycol monododecyl ether; laureth 9, i.e., a mixture of polyethylene glycol monododecyl ethers averaging about 9 ethylene oxide groups per molecule; monoethanolamine; nonoxynol 4, 9 and 10, i.e., polyethylene glycol mono(p-nonylphenyl) ether; nonoxynol 15, i. e.,  $\alpha$ -(p-nonylphenyl)- $\omega$ -hydroxypenta-deca(oxyethylene); nonoxynol 30, i.e. ,  $\alpha$ -(p-nonylphenyl)- $\omega$ -hydroxytriaconta(oxyethylene); poloxalene, i.e., nonionic polymer of the polyethylenepolypropylene glycol type, MW = approx. 3000; poloxamer, referred to in the discussion of ointment bases further above; polyoxyl 8, 40 and 50 stearate, i.e., poly(oxy-1,2-ethanediyl),  $\alpha$ -hydro- $\omega$ -hydroxy-; octadecanoate; polyoxyl 10 oleyl ether, i.e., poly(oxy-1,2-ethanediyl),  $\alpha$ -[(Z)-9-octadecenyl- $\omega$ -hydroxy-; polysorbate 20, i.e., sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl); polysorbate 40, i.e., sorbitan, monohexadecanoate, poly(oxy-1,2-ethanediyl); polysorbate 60, i.e., sorbitan, mono-octadecanoate, poly(oxy-1,2-ethanediyl); polysorbate 65, i.e., sorbitan, tri-octadecanoate, poly(oxy-1,2-ethanediyl); polysorbate 80,

i.e., sorbitan, mono-9 -monodecenoate, poly(oxy-1,2-ethanediyl); polysorbate 85, i.e., sorbitan, tri-9-octadecenoate, poly(oxy-1,2-ethanediyl); sodium lauryl sulfate; sorbitan monolaurate; sorbitan monooleate; sorbitan monopalmitate; sorbitan monostearate; sorbitan sesquioleate; sorbitan trioleate; and sorbitan tristearate.

The pharmaceutical compositions of the present invention may be prepared using very straightforward methodology which is well understood by the artisan of ordinary skill. Where the pharmaceutical compositions of the present invention are simple aqueous and/or other solvent solutions, the various components of the overall composition are brought together in any practical order, which will be dictated largely by considerations of convenience. Those components having reduced water solubility, but sufficient solubility in the same co-solvent with water, may all be dissolved in said co-solvent, after which the co-solvent solution will be added to the water portion of the carrier whereupon the solutes therein will become dissolved in the water. To aid in this dispersion/solution process, a surfactant may be employed.

Where the pharmaceutical compositions of the present invention are to be in the form of emulsions, the components of the pharmaceutical composition will be brought together in accordance with the following general procedures. The continuous water phase is first heated to a temperature in the range of from about 60° to about 95°C, preferably from about 70° to about 85°C, the choice of which temperature to use being dependent upon the physical and chemical properties of the components which make up the oil-in-water emulsion. Once the continuous water phase has reached its selected temperature, the components of the final composition to be added at this stage are admixed with the water and dispersed therein under high-speed agitation. Next, the temperature of the water is restored to approximately its original level, after which the components of the composition which comprise the next stage are added

5 to the composition mixture under moderate agitation and mixing continues for from about 5 to about 60 minutes, preferably about 10 to about 30 minutes, depending on the components of the first two stages. Thereafter, the composition mixture is passively or actively cooled to from about 20° to about 55°C for addition of any components in the remaining stages, after which water is added in sufficient quantity to reach its original predetermined concentration in the overall composition.

10 According to the present invention, the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable  
15 dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3- butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium  
20 chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation  
25 of injectables, as do natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Rh, HCIX or similar alcohol.

30 The pharmaceutical compositions of the present invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case  
35 of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents

include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added. Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of the present invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation, as described above, or in a suitable enema formulation. Topically active transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

Pharmaceutical compositions within the scope of the present invention include those wherein the therapeutically effective amount of an active ingredient comprising a preferred compound required for treating or  
5 preventing diseases, disorders, and conditions mediated by or associated with modulation of PDE4 activity as described herein, is provided in a dosage form suitable for systemic administration. Such a pharmaceutical composition will contain said active ingredient in suitable liquid form for  
10 delivery by: (1) injection or infusion which is intraarterial, intra- or transdermal, subcutaneous, intramuscular, intraspinal, intrathecal, or intravenous, wherein said active ingredient: (a) is contained in solution as a solute; (b) is contained in the discontinuous phase of an emulsion, or the  
15 discontinuous phase of an inverse emulsion which inverts upon injection or infusion, said emulsions containing suitable emulsifying agents; or (c) is contained in a suspension as a suspended solid in colloidal or micro-particulate form, said suspension containing suitable suspending agents;  
20 (2) injection or infusion into suitable body tissues or cavities as a depot, wherein said composition provides storage of said active ingredient and thereafter delayed-, sustained-, and/or controlled-release of said active ingredient for systemic distribution; (3) instillation, inhalation or insufflation into suitable body tissues or cavities of said pharmaceutical composition in  
25 suitable solid form, where said active ingredient: (a) is contained in a solid implant composition providing delayed-, sustained-, and/or controlled-release of said active ingredient; (b) is contained in a particulate composition to be inhaled into the lungs; or (c) is contained in a particulate  
30 composition to be blown into suitable body tissues or cavities, where said composition optionally provides delayed-, sustained-, and/or controlled-release of said active ingredient; or (4) ingestion of said pharmaceutical composition in suitable solid or liquid form for peroral delivery of said active  
35 ingredient, where said active ingredient is contained in a solid dosage form; or (b) is contained in a liquid dosage form.

Particular dosage forms of the above-described pharmaceutical compositions include (1) suppositories as a special type of implant, comprising bases which are solid at room temperature but melt at body temperature, slowly releasing the active ingredient with which they are impregnated into the surrounding tissue of the body, where the active ingredient becomes absorbed and transported to effect systemic administration; (2) solid peroral dosage forms selected from the group consisting of (a) delayed-release oral tablets, capsules, caplets, lozenges, troches, and multiparticulates; (b) enteric-coated tablets and capsules which prevent release and absorption in the stomach to facilitate delivery distal to the stomach of the patient being treated; (c) sustained-release oral tablets, capsules and microparticulates which provide systemic delivery of the active ingredient in a controlled manner up to a 24-hour period; (d) fast-dissolving tablets; (e) encapsulated solutions; (f) an oral paste; (g) a granular form incorporated in or to be incorporated in the food of a patient being treated; and (h) liquid peroral dosage forms selected from the group consisting of solutions, suspensions, emulsions, inverse emulsions, elixirs, extracts, tinctures, and concentrates.

Pharmaceutical compositions within the scope of the present invention include those wherein the therapeutically effective amount of an active ingredient comprising a compound of the present invention required for treating or preventing diseases, disorders, and conditions mediated by or associated with modulation of PDE4 activity as described herein is provided in a dosage form suitable for local administration to a patient being treated, wherein said pharmaceutical composition contains said active ingredient in suitable liquid form for delivering said active ingredient by: (1) injection or infusion into a local site which is intraarterial, intraarticular, intrachondrial, intracostal, intracystic, intra- or transdermal, intrafascicular, intraligamentous, intramedullary, intramuscular, intranasal, intraneural, intraocular, i.e., ophthalmic administration, intraosteal, intrapelvic, intrapericardial, intraspinal, intrasternal, intrasynovial,

intratarsal, or intrathecal; including components which provide delayed-release, controlled-release, and/or sustained-release of said active ingredient into said local site; where said active ingredient is contained: (a) in solution as a solute; (b) in the discontinuous phase of an emulsion, or the discontinuous phase of an inverse emulsion which inverts upon injection or infusion, said emulsions containing suitable emulsifying agents; or (c) in a suspension as a suspended solid in colloidal or microparticulate form, said suspension containing suitable suspending agents; or (2) injection or infusion as a depot for delivering said active ingredient to said local site; wherein said composition provides storage of said active ingredient and thereafter delayed-, sustained-, and/or controlled- release of said active ingredient into said local site, and wherein said composition also includes components which ensure that said active ingredient has predominantly local activity, with little systemic carryover activity; or wherein said pharmaceutical composition contains said active ingredient in suitable solid form for delivering said inhibitor by: (3) instillation, inhalation or insufflation to said local site, where said active ingredient is contained: (a) in a solid implant composition which is installed in said local site, said composition optionally providing delayed-, sustained-, and/or controlled-release of said active ingredient to said local site; (b) in a particulate composition which is inhaled into a local site comprising the lungs; or (c) in a particulate composition which is blown into a local site, where said composition includes components which will ensure that said active ingredient has predominantly local activity, with insignificant systemic carryover activity, and optionally provides delayed-, sustained-, and/or controlled release of said active ingredient to said local site. For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspension in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

5 The pharmaceutical compositions of the present invention may also be administered by nasal aerosol or inhalation through the use of a nebulizer, a dry powder inhaler or a metered dose inhaler. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, hydrofluorocarbons, and/or other conventional solubilizing or dispersing agents.

15 As already mentioned, the preferred compounds of the present invention may be administered systemically to a patient to be treated as a pharmaceutical composition in suitable liquid form by injection or infusion. There are a number of sites and organ systems in the body of the patient which will allow the properly formulated pharmaceutical composition, once injected or infused, to permeate the entire body and all of the organ system of the patient being treated. An injection is a single dose of the pharmaceutical composition forced, usually by a syringe, into the tissue involved. The most common types of injections are intramuscular, intravenous, and subcutaneous. By contrast, an infusion is the gradual introduction of the pharmaceutical composition into the tissue involved.

25 The most common type of infusion is intravenous. Other types of injection or infusion comprise intraarterial, intra- or transdermal (including subcutaneous), or intraspinal especially intrathecal. In these liquid pharmaceutical compositions, the active ingredient may be contained in solution as the solute. This is the most common and most preferred type of such composition, but requires an active ingredient in a salt form that has reasonably good aqueous solubility. Water (or saline) is by far the most preferred solvent for such compositions. Occasionally supersaturated solutions may be utilized, but these present stability problems that make

30 them impractical for use on an everyday basis.

35



If it is not possible to obtain a form of some preferred compound that has the requisite degree of aqueous solubility, as may sometimes occur, it is, within the skill of the artisan to prepare an emulsion, which is a dispersion of small globules of one liquid, the discontinuous or internal phase, throughout a second liquid, the continuous or external phase, with which it is immiscible. The two liquids are maintained in an emulsified state by the use of emulsifiers which are pharmaceutically acceptable. Thus, if the active ingredient is a waterinsoluble oil, it can be administered in, an emulsion of which it is the discontinuous phase. Also where the active ingredient is water-insoluble but can be dissolved in a solvent which is immiscible with water, an emulsion can be used. While the active ingredient would most commonly be used as the discontinuous or internal phase of what is referred to as an oil-in- water emulsion, it could also be used as the discontinuous or internal phase of an inverse emulsion, which is commonly referred to as a water-in- oil emulsion. Here the active ingredient is soluble in water and could be administered as a simple aqueous solution. However, inverse emulsions invert upon injection or infusion into an aqueous medium such as the blood, and offer the advantage of providing a more rapid and efficient dispersion of the active ingredient into that aqueous medium than can be obtained using an aqueous solution. Inverse emulsions are prepared by using suitable, pharmaceutically acceptable emulsifying agents well known in the art. Where the active ingredient has limited water solubility, it may also be administered as a suspended solid in colloidal or microparticulate form in a suspension prepared using suitable, pharmaceutically acceptable suspending agents. The suspended solids containing the active ingredient may also be formulated as delayed-, sustained-, and/or controlled-release compositions.

While systemic administration will most frequently be carried out by injection or infusion of a liquid, there are many situations in which it will be advantageous or even necessary to deliver the active ingredient as a solid.

Systemic administration of solids is carried out by instillation, inhalation or insufflation of a pharmaceutical composition in suitable solid form containing the active ingredient. Instillation of the active ingredient may entail installing a solid implant composition into suitable body tissues or cavities. The implant may comprise a matrix of bio-compatible and bio-erodible materials in which particles of a solid active ingredient are dispersed, or in which, possibly, globules or isolated cells of a liquid active ingredient are entrapped. Desirably, the matrix will be broken down and completely absorbed by the body. The composition of the matrix is also preferably selected to provide controlled-, sustained-, and/or delayed release of the active ingredient over extended periods of time, even as much as several months.

The term "implant" most often denotes a solid pharmaceutical composition containing the active ingredient, while the term "depot" usually implies a liquid pharmaceutical composition containing the active ingredient, which is deposited in any suitable body tissues or cavities to form a reservoir or pool which slowly migrates to surrounding tissues and organs and eventually becomes systemically distributed. However, these distinctions are not always rigidly adhered to in the art, and consequently, it is contemplated that there is included within the scope of the present invention liquid implants and solid depots, and even mixed solid and liquid forms for each. Suppositories may be regarded as a type of implant, since they comprise bases which are solid at room temperature but melt at a patient's body temperature, slowly releasing the active ingredient with which they are impregnated into the surrounding tissue of the patient's body, where the active ingredient becomes absorbed and transported to effect systemic administration.

Systemic administration can also be accomplished by inhalation or insufflation of a powder, i.e., particulate composition containing the active

ingredient. For example, the active ingredient in powder form may be inhaled into the lungs using conventional devices for aerosolizing particulate formulations. The active ingredient as a particulate formulation may also be administered by insufflation, i.e., blown or otherwise dispersed  
5 into suitable body tissues or cavities by simple dusting or using conventional devices for aerosolizing particulate formulations. These particulate compositions may also be formulated to provide delayed-, sustained-, and/or controlled- release of the active ingredient in  
10 accordance with well understood principles and known materials.

Other means of systemic administration which may utilize the active ingredients of the present invention in either liquid or solid form include transdermal, intranasal, and ophthalmic routes. In particular, transdermal  
15 patches prepared in accordance with well known drug delivery technology may be prepared and applied to the skin of a patient to be treated, whereafter the active- agent by reason of its formulated solubility characteristics migrates across the epidermis and into the dermal layers of  
20 the patient's skin where it is taken up as part of the general circulation of the patient, ultimately providing systemic distribution of the active ingredient over a desired, extended period of time. Also included are implants which are placed beneath the epidermal layer of the skin, i. e.  
25 between the epidermis and the dermis of the skin of the patient being treated. Such an implant will be formulated in accordance with well known principles and materials commonly used in this delivery technology, and may be prepared in such a way as to provide controlled-, sustained-,  
30 and/or delayed-release of the active ingredient into the systemic circulation of the patient. Such subepidermal (subcuticular) implants provide the same facility of installation and delivery efficiency as transdermal patches, but without the limitation of being subject to degradation, damage or accidental removal as a consequence of being exposed on the top layer of the  
35 patient's skin.

In the above description of pharmaceutical compositions containing a preferred compound, the equivalent expressions: "administration", "administration of", "administering", and "administering a" have been used with respect to said pharmaceutical compositions. As thus employed,  
5 these

expressions are intended to mean providing to a patient in need of treatment a pharmaceutical composition of the present invention by any of the routes of administration herein described, wherein the active ingredient  
10 is a preferred compound or a prodrug, derivative, or metabolite thereof which is useful in treating a disease, disorder, or condition mediated by or associated with modulation of PDE4 activity in said patient. Accordingly, there is included within the scope of the present invention any other  
15 compound which, upon administration to a patient, is capable of directly or indirectly providing a preferred compound. Such compounds are recognized as prodrugs, and a number of established procedures are available for preparing such prodrug forms of the preferred compounds.

20 The dosage and dose rate of the compounds effective for treating or preventing a disease, disorder, or condition mediated by or associated with modulation of PDE4 activity, will depend on a variety of factors, such as the nature of the inhibitor, the size of the patient, the goal of the treatment,  
25 the nature of the pathology to be treated, the specific pharmaceutical composition used, and the observations and conclusions of the treating physician.

30 For example, where the dosage form is oral, e.g., a tablet or capsule, suitable dosage levels of the preferred compounds will be between about 0.1  $\mu\text{g/kg}$  and about 50.0  $\text{mg/kg}$  of body weight per day, preferably between about 5.0  $\mu\text{g/kg}$  and about 5.0  $\text{mg/kg}$  of body weight per day,  
35 more preferably between about 10.0  $\mu\text{g/kg}$  and about 1.0  $\text{mg/kg}$  of body weight per day, and most preferably between about 20.0  $\mu\text{g/kg}$  and

about 0.5 mg/kg of body weight per day of the active ingredient.

Where the dosage form is topically administered to the bronchia and lungs, e.g., by means of a powder inhaler or nebulizer, suitable dosage  
5 levels of the compounds will be between about 0.001  $\mu\text{g/kg}$  and about 10.0 mg/kg of body weight per day, preferably between about 0.5  $\mu\text{g/kg}$  and about 0.5 mg/kg of body weight per day, more preferably between about 1.0  $\mu\text{g/kg}$  and about 0.1 mg/kg of body weight per day, and most  
10 preferably between about 2.0  $\mu\text{g/kg}$  and about 0.05 mg/kg of body weight per day of the active ingredient.

Using representative body weights of 10 kg and 100 kg in order to illustrate  
15 the range of daily oral dosages which might be used as described above, suitable dosage levels of the preferred compounds will be between about 1.0 - 10.0  $\mu\text{g}$  and 500.0 - 5000.0 mg per day, preferably between about 50.0 - 500.0  $\mu\text{g}$  and 50.0 - 500.0 mg per day, more preferably between  
20 about 100.0 - 1000.0  $\mu\text{g}$  and 10.0 - 100.0 mg per day, and most preferably between about 200.0 - 2000.0  $\mu\text{g}$  and about 5.0 - 50.0 mg per day of the active ingredient comprising a preferred compound. These ranges of dosage amounts represent total dosage amounts of the active ingredient  
25 per day for a given patient. The number of times per day that a dose is administered will depend upon such pharmacological and pharmacokinetic factors as the half-life of the active ingredient, which reflects its rate of catabolism and clearance, as well as the minimal and optimal blood plasma or other body fluid levels of said active ingredient attained in the  
30 patient which are required for therapeutic efficacy.

Numerous other factors must also be considered in deciding upon the number of doses per day and the amount of active ingredient per dose that  
35 will be administered. Not the least important of such other factors is the individual response of the patient being treated. Thus, for example, where

- 77 -

the active ingredient is used to treat or prevent asthma, and is administered topically via aerosol inhalation into the lungs, from one to four doses consisting of actuations of a dispensing device, i.e., "puffs" of an inhaler, will be administered. each day, each dose containing from about 5 50.0  $\mu$ g to about 10.0 mg of active ingredient.

10

15

20

25


30

35

# Patent claims

## 1. Use of

a) compounds of formula I disclosed in EP 0763534



in which

B is an aromatic heterocycle having 1 to 4 N, O and/or S atoms, bonded via N or C, which can be unsubstituted or mono-, di- or trisubstituted by Hal, A and/or OA, and can also be fused to a benzene or pyridine ring,

Q is absent or is alkylene having 1-6 C atoms,

X is CH<sub>2</sub>, S or O,

R<sup>1</sup> and R<sup>2</sup> in each case independently of one another are H or A,

R<sup>3</sup> and R<sup>4</sup> in each case independently of one another are -OH, OR<sup>5</sup>, -S-R<sup>5</sup>, -SO-R<sup>5</sup>, -SO<sub>2</sub>-R<sup>5</sup>, Hal, methylenedioxy, -NO<sub>2</sub>, -NH<sub>2</sub>, -NHR<sup>5</sup> or -NR<sup>5</sup>R<sup>6</sup>,


R<sup>5</sup> and R<sup>6</sup> in each case independently of one another are A, cycloalkyl having 3-7 C atoms, methylenecycloalkyl having 4-8 C atoms or alkenyl having 2-8 C atoms,

A is alkyl having 1 to 10 C atoms, which can be substituted by 1 to 5 F and/or Cl atoms and

Hal is F, Cl, Br or I

and their stereoisomers and physiologically acceptable, salts and solvates;

b) compounds of formula I disclosed in WO 99/65880



10 in which

B is a phenyl ring which is unsubstituted or mono- or polysubstituted by  $R^3$ ,

Q is absent or is alkylene having 1-4 C atoms,

15  $R^1, R^2$  each independently of one another are  $-OR^4$ ,  $-S-R^4$ ,  $-SO-R^4$ ,  $-SO_2-R^4$  or Hal,

$R^1$  and  $R^2$  together are also  $-O-CH_2-O-$ ,

$R^3$  is  $R^4$ , Hal, OH,  $OR^4$ , OPh,  $NO_2$ ,  $NHR^4$ ,  $N(R^4)_2$ ,  $NHCO-R^4$ ,  $NHSO_2-R^4$  or  $NHCOOR^4$ ,

20  $R^4$  is A, cycloalkyl having 3-7 C atoms, alkylencycloalkyl having 5-10 C atoms or alkenyl having 2-8 C atoms,


A is alkyl having 1 to 10 C atoms, which can be substituted by 1 to 5 F and/or Cl atoms and

25 Hal is F, Cl, Br or I,

and their physiologically acceptable salts and solvates;

c) compounds of formula I disclosed in WO 99/08047

30



35



- 80 -

in which

$R^1, R^2$  in each case independently of one another are  $-OH$ ,  $OR^5$ ,  $-S-R^5$ ,  $-SO-R^5$ ,  $-SO_2-R^5$  or Hal,

$R^1$  and  $R^2$  together are also  $-O-CH_2-O-$ ,

$R^3$  is  $NH_2$ , NHA, NAA' or a saturated heterocycle having 1 to 4 N, O and/or S atoms which can be unsubstituted or mono-, di- or tri-substituted by Hal, A and/or OA,

Q is absent or is branched or unbranched alkylene having 1-10 C atoms,


$R^5$  is A, cycloalkyl having 3-7 C atoms, alkylencycloalkyl having 4-8 C atoms or alkenyl having 2-8 C atoms,

A, A' in each case independently of one another are alkyl which has 1 to 10 C atoms and which can be substituted by 1 to 5 F and/or Cl atoms and

Hal is F, Cl, Br or I;

and the physiologically acceptable salts and solvates thereof;

d) compounds of formula I disclosed in WO 98/06704



in which

B is A, OA,  $NH_2$ , NHA, NAA' or an unsaturated heterocycle which has 1 to 4 N, O and/or S atoms and which can be unsubstituted or mono-, di- or trisubstituted by Hal, A and/or OA,


Q is absent or is alkylene having 1-6 C atoms,

$R^1, R^2$  in each case independently of one another are  $-OH$ ,  $OR^5$ ,  
 $-S-R^5$ ,  $-SO-R^5$ ,  $-SO_2-R^5$ ,  $Hal$ ,  $-NO_2$ ,  $-NH_2$ ,  $-NHR^5$  or  $-NR^5R^6$ ,  
 $R^1$  and  $R^2$  together are also  $-O-CH_2-O-$ ,  
 $R^3, R^4$  in each case independently of one another are  $H$  or  $A$ ,  
5  $R^5, R^6$  in each case independently of one another are  $A$ , cycloalkyl  
having 3-7 C atoms, methylenecycloalkyl having 4-8 C atoms  
or alkenyl having 2-8 C atoms,  
 $A, A'$  in each case independently of one another are alkyl which  
10 has 1 to 10 C atoms and which can be substituted by 1 to 5 F  
and/or Cl atoms and  
 $Hal$  is F, Cl, Br or I,  
and the stereoisomers and physiologically acceptable salts and solvates  
15 thereof;

e) compounds disclosed in WO 00/59890  
1-(4-ureidobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-  
tetrahydropyridazine,  
20 1-(4-nicotinoylaminobenzoyl)-3-(3-propoxy-4-methoxyphenyl)-1,4,5,6-  
tetrahydropyridazine,  
1-(4-trifluoroacetamidobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
25 1-(4-ethoxycarbonylaminobenzoyl)-3-(3-propoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
1-(4-isopropoxycarbonylaminobenzoyl)-3-(3-ethoxy-4-  
methoxyphenyl)-1,4,5,6-tetrahydropyridazine,  
30 1-(4-propoxycarbonylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-  
1,4,5,6-tetrahydropyridazine,  
1-(4-nicotinoylaminobenzoyl)-3-(3,4-dimethoxyphenyl)-4-ethyl-  
1,4,5,6-tetrahydropyridazine,  
35 1-(4-ethoxycarbonylaminobenzoyl)-3-(3,4-dimethoxyphenyl)-4-ethyl-  
1,4,5,6-tetrahydropyridazine and

1-(4-acetamidobenzoyl)-3-(3,4-dimethoxyphenyl)-4-ethyl-1,4,5,6-tetrahydropyridazine,  
and their physiologically acceptable salts and solvates;

5 f) compounds of formula I disclosed in DE 19604388



15 in which

R<sup>1</sup>, R<sup>2</sup> in each case independently of one another are H or A,  
R<sup>3</sup>, R<sup>4</sup> in each case independently of one another are -OH, OA,  
-S-A, -SO-A, -SO<sub>2</sub>-A, Hal, methylenedioxy, -NO<sub>2</sub>, -NH<sub>2</sub>,  
-NHA or -NAA',

20 A, A' in each case independently of one another are alkyl having 1 to 10 C-atoms, and which can be substituted by 1 to 5 F and/or Cl atoms, cycloalkyl having 3-7 C atoms or methylenecycloalkyl having 4-8 C atoms,

25 B is -Y-R<sup>5</sup> oder -O-Y-R<sup>5</sup>,

Q is absent or is alkylene having 1-4 C atoms,

Y is absent or is alkylene having 1-10 C atoms,

X is CH<sub>2</sub> or S,

30 R<sup>5</sup> is NH<sub>2</sub>, NHA, NAA' or is a saturated 3-8 membered heterocycle having at least one N atom, and wherein other CH<sub>2</sub> groups optionally may be replaced by NH, NA, S or O, which can be unsubstituted or monosubstituted by A or OH,


35 Hal is F, Cl, Br oder I

and the stereoisomers and physiologically acceptable salts and solvates thereof;

g) compounds of formula I disclosed in DE 19932315

5

10



15

in which

$R^1, R^2$  in each case independently of one another are H, OH, OA, SA, SOA,  $SO_2A$ , F, Cl or  $A'_2N-(CH_2)_n-O-$ ,

20

$R^1$  and  $R^2$  together are also  $-O-CH_2-O-$ ,

$R^3, R^4$  in each case independently of one another are H, A, Hal, OH, OA,  $NO_2$ , NHA,  $NA_2$ , CN, COOH, COOA, NHCOA,  $NHSO_2A$  or  $NHCOOA$ ,

25

$R^5, R^6$  in each case independently of one another are H or alkyl having 1 to 6 C atoms,

A is alkyl having 1 to 10 C atoms, which can be substituted by 1 to 5 F and/or Cl atoms, is cycloalkyl having 3-7 C atoms, alkylencycloalkyl having 5-10 C atoms or alkenyl having 2-8 C atoms,

30

$A'$  is alkyl having 1, 2, 3, 4, 5 or 6 C atoms,


n is 1, 2, 3 or 4,

Hal is F, Cl, Br or I,

35

and their physiologically acceptable salts and solvates;

h) compounds of formula I disclosed in EP 0723962



10 in which

R¹ and R² in each case independently of one another are H or A,

R³ and R⁴ in each case independently of one another are -OH, -OR¹⁰, -S-R¹⁰, -SO-R¹⁰, -SO₂R¹⁰, Hal, methylenedioxy, -NO₂, -NH₂, -NHR¹⁰ or -NR¹⁰R¹¹,

15

R⁵ is a phenyl radical which is unsubstituted or mono- or disubstituted by R⁶ and/or R⁷,

Q is absent or is alkylene having 1-6 C atoms,

20

R⁶ and R⁷ in each case independently of one another are -NH₂, -NR⁸R⁹, -NHR¹⁰, -NR¹⁰R¹¹, -NO₂, Hal, -CN, -OA, -COOH or -COOA,

R⁸ and R⁹ in each case independently of one another are H, acyl having 1-8 C atoms which can be substituted by 1-5 F and/or Cl atoms, -COOA, -S-A, -SO-A, -SO₂A, -CONH₂, -CONHA, -CONA₂, -CO-COOH, -CO-COOA, -CO-CONH₂, -CO-CONHA or -CO-CONA₂,

25

A is alkyl having 1 to 6 C atoms which can be substituted by 1-5 F and/or Cl atoms,

30

R¹⁰ and R¹¹ in each case independently of one another are A, cycloalkyl having 3-7 C atoms, methylenecycloalkyl having 4-8 C atoms or alkenyl having 2-8 C-atoms

35

and


Hal is F, Cl, Br or I,

and their physiologically acceptable salts and solvates;

i) compounds of formula I disclosed in EP 0738715

5

10



in which

15

$R^1$  and  $R^2$  in each case independently of one another are H or A,  
 $R^3$  and  $R^4$  in each case independently of one another are -OH, -OR<sup>10</sup>,  
 -S-R<sup>10</sup>, -SO-R<sup>10</sup>, -SO<sub>2</sub>R<sup>10</sup>, Hal, methylenedioxy, -NO<sub>2</sub>, -NH<sub>2</sub>,  
 -NHR<sup>10</sup> or -NR<sup>10</sup>R<sup>11</sup>,

$R^5$  is a phenyl radical which is unsubstituted or mono- or  
 disubstituted by  $R^6$  and/or  $R^7$ ,

20

Q is absent or is alkylene having 1-6 C atoms,  
 $R^6$  and  $R^7$  in each case independently of one another are -NH<sub>2</sub>,  
 -NR<sup>8</sup>R<sup>9</sup>, -NHR<sup>10</sup>, -NR<sup>10</sup>R<sup>11</sup>, -NO<sub>2</sub>, Hal, -CN, -OA, -COOH or  
 -COOA,

25

$R^8$  and  $R^9$  in each case independently of one another are H, acyl having  
 1-8 C atoms which can be substituted by 1-5 F and/or Cl  
 atoms, -COOA, -SO-A, -SO<sub>2</sub>A, -CONH<sub>2</sub>, -CONHA, -CONA<sub>2</sub>,  
 -CO-COOH, -CO-COOA, -CO-CONH<sub>2</sub>,  
 -CO-CONHA or -CO-CONA<sub>2</sub>,

30

A is alkyl having 1 to 6 C atoms which can be substituted by 1-5  
 F and/or Cl atoms,

$R^{10}$  and  $R^{11}$  in each case independently of one another are A, cycloalkyl  
 having 3-7 C atoms, methylenecycloalkyl having 4-8 C atoms  
 or alkenyl having 2-8 C-atoms

35


and

Hal is F, Cl, Br or I,  
and their physiologically acceptable salts and solvates;

j) compounds of formula I disclosed in EP 0 618 201

5

10



in which

15

$R^1$  and  $R^2$  in each case independently of one another are H or A,  
 $R^3$  and  $R^4$  in each case independently of one another are OH, OA, SA,  
SOA,  $SO_2A$ , Hal, methylenedioxy, cycloalkyloxy with 3-7 C-  
atoms or  $O-C_mH_{2m+1-k}F_k$ ,

20

$R^5$  is  $-NR^6R^7$  or  $-N(CH_2)_n$ ,

wherein one  $CH_2$ -group may be replaced by oxygen,

$R^6$  and  $R^7$  in each case independently of one another are H or A,

25

Q is alkylen with 1-6 C-atoms,

A is alkyl with 1-6 C-atoms,

Hal is F, Cl, Br or I,

m is 1, 2, 3, 4, 5 or 6,

n 3, 4, 5 oder 6,


30

k 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 oder 13

and their physiologically acceptable salts and solvates;

k) compounds of formula I disclosed in EP 0 539 806

35



5

in which

- $R^1$  and  $R^2$  in each case independently of one another are H or A,  
 $R^3$  is H, OA or  $O-C_mH_{2m+1-n}X_n$ ,  
 $R^4$  is  $-O-C_mH_{2m+1-n}X_n$ ,  
X is F or Cl,  
A is alkyl with 1-6 C-atoms,  
m is 1, 2, 3, 4, 5 or 6 and  
n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13  
and their physiologically acceptable salts and solvates;

15

for preparing a medicament for treating a subject suffering from a disease or condition mediated by the PDE4 isozyme in its role of regulating the activation and degranulation of human eosinophils.

20

2. Use according to claim 1 of

25

a) compounds disclosed in EP 0763534:

2-(3-nicotinoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

30

2-(2-nicotinoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-nicotinoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

35

2-(3-nicotinoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,



2-(2-nicotinoylaminobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-nicotinoylaminobenzyl)-6-(3-methoxy-4-trifluoromethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

5 2-(4-nicotinoylaminobenzyl)-6-(3-methoxy-4-difluoromethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-nicotinoylaminobenzyl)-6-(3-methoxy-4-fluoromethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

10 2-(4-nicotinoylaminobenzyl)-6-(3-difluoromethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-nicotinoylaminobenzyl)-6-(3-trifluoromethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

15 2-(4-nicotinoylaminobenzyl)-6-(3-fluoromethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-nicotinoylaminobenzyl)-6-(3-methoxy-4-ethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

20 2-(4-nicotinoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-nicotinoylaminobenzyl)-6-(3-hydroxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

25 2-(4-nicotinoylaminobenzyl)-6-(4-methylsulfonylphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-nicotinoylaminobenzyl)-6-(4-methyleneoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

30 2-(4-nicotinoylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(3-nicotinoylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-nicotinoylaminophenethyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

35 2-(4-nicotinoylaminophenethyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

3-(4-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-  
1,3,4-thiadiazin-2-one,

3-(3-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-  
1,3,4-thiadiazin-2-one,

5 3-(2-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-  
1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

10 3-(3-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

3-(2-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

15 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-  
6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-  
6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

20 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-  
ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-  
6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

25 3-(4-nicotinoylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-  
6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-  
ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

30 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

35 3-(4-nicotinoylaminobenzyl)-5-(3-hydroxy-4-methoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(4-methylsulfonylphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(4-methyleneoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

5 3-(4-nicotinoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(3-nicotinoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

10 3-(4-nicotinoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,

3-(4-nicotinoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-one,

15 3-(4-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-oxadiazin-2-one,

3-(3-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-oxadiazin-2-one,

20 3-(2-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-1,3,4-oxadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,

25 3-(3-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,

3-(2-nicotinoylaminobenzyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,

30 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-trifluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-difluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,

35 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-fluoromethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,

3-(4-nicotinoylaminobenzyl)-5-(3-difluoromethoxy-4-methoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,

- 3-(4-nicotinoylaminobenzyl)-5-(3-trifluoromethoxy-4-methoxyphenyl)-  
6-ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(3-fluoromethoxy-4-methoxyphenyl)-6-  
ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 5 3-(4-nicotinoylaminobenzyl)-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-oxadiazin-2-one,
- 10 3-(4-nicotinoylaminobenzyl)-5-(3-hydroxy-4-methoxyphenyl)-6-ethyl-  
3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(4-methylsulfonylphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-oxadiazin-2-one,
- 15 3-(4-nicotinoylaminobenzyl)-5-(4-methyleneoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-  
ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 20 3-(3-nicotinoylaminobenzyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-6-  
ethyl-3,6-dihydro-1,3,4-oxadiazin-2-one,
- 3-(4-nicotinoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-3,6-dihydro-  
1,3,4-oxadiazin-2-one,
- 25 3-(4-nicotinoylaminophenethyl)-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-  
dihydro-1,3,4-oxadiazin-2-one,
- 2-(3-nicotinoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-  
tetrahydropyridazin-3-one,
- 2-(4-isonicotinoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-  
tetrahydropyridazin-3-one,
- 30 2-(4-pyrazinecarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-(isoxazole-5-carbonylamino)benzyl)-6-(3-ethoxy-4-  
methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,
- 35 2-(4-nicotinoylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,

2-(4-nicotinoylaminobenzyl)-6-(3,4,-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one, hydrochloride,  
and their stereoisomers and physiologically acceptable, salts and solvates;

5 b) . compounds disclosed in WO 99/65880

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-methoxybenzoyl-3-carboxamide,

10 N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-methylbenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)benzoyl-3-carboxamide,

15 N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-3,4-dichlorobenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-trifluoromethylbenzoyl-3-carboxamide,

20 N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-3-chlorobenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-fluorobenzoyl-3-carboxamide,

25 N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-butoxybenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-pentoxybenzoyl-3-carboxamide,

30 N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-ethoxybenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-3,4-dimethoxybenzoyl-3-carboxamide,

35 N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-3-methylbenzoyl-3-carboxamide,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-3-methoxybenzoyl-3-carboxamide,

and their physiologically acceptable salts and solvates;

c) compounds disclosed in WO 99/08047

5           3-dimethylaminopropyl {4-[3-(3-ethoxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,  
          N-methylpiperidin-4-yl-{4-[3-(3-ethoxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,  
10          3-dimethylaminopropyl {4-[3-(3-isopropoxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,  
          3-dimethylaminopropyl {3-[3-(3-ethoxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,  
15          3-dimethylaminopropyl{3-[3-(3-cyclopentyloxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,  
          N-methylpiperidin-4-yl-{3[3-(3-cyclopentyloxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,  
20          3-dimethylaminopropyl{3-[3-(3-propyloxy-4-methoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate,  
          3-dimethylaminopropyl{4-[3-(3,4-diethoxyphenyl)-1,2,3,4-tetrahydro-  
pyridazin-1-ylcarbonyl]phenyl}carbamate,  
          N-methylpiperidin-4-yl-{4-[3-(3,4-diethoxyphenyl)-1,2,3,4-tetrahydro-  
25       pyridazin-1-ylcarbonyl]phenyl}carbamate,  
          3-dimethylaminopropyl{3-[3-(3,4-dimethoxyphenyl)-  
1,2,3,4-tetrahydropyridazin-1-ylcarbonyl]phenyl}carbamate  
          3-dimethylaminopropyl{4-[3-(3,4-dimethoxyphenyl)-1,2,3,4-tetra-  
30       hydropyridazin-1-ylcarbonyl]phenyl}carbamate,  
and the physiologically acceptable salts and solvates thereof;

d) compounds disclosed in WO 98/06704

35           1-(4-nicotinoylaminobenzoyl)-3-(3,4-dimethoxyphenyl)-1,4,5,6-  
tetrahydropyridazine,

1-(3-nicotinoylaminobenzoyl)-3-(3,4-dimethoxy-phenyl)-1,4,5,6-tetrahydropyridazine hydrochloride,

1-(2-nicotinoylaminobenzoyl)-3-(3,4-dimethoxy-phenyl)-1,4,5,6-tetrahydropyridazine,

5 1-(4-nicotinoylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazine,

1-(3-nicotinoylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazine,

10 1-(4-nicotinoylaminobenzoyl)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazine,

1-(3-nicotinoylaminobenzoyl)-3-(3-cyclopentyloxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazine,

15 1-(4-nicotinoylaminobenzoyl)-3-(3,4-methylene-dioxyphenyl)-1,4,5,6-tetrahydropyridazine,

1-(4-nicotinoylaminobenzoyl)-3-(3-methoxy-4-methylsulfonylphenyl)-1,4,5,6-tetrahydro-pyridazine,

20 1-(4-nicotinoylaminobenzoyl)-3-(3-trifluoro-methoxy-4-methoxyphenyl)-1,4,5,6-tetrahydro-pyridazine,

1-(4-ethoxy-carbonylaminobenzoyl)-3-(3,4-dimethoxyphenyl)-1,4,5,6-tetrahydropyridazine,

25 1-(3-ethoxycarbonylaminobenzoyl)-3-(3,4-dimethoxy-phenyl)-1,4,5,6-tetrahydropyridazine,

1-(2-ethoxycarbonylaminobenzoyl)-3-(3,4-dimethoxy-phenyl)-1,4,5,6-tetrahydropyridazine,

30 1-(4-ethoxycarbonylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazine,

1-(3-ethoxycarbonylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazine,

35 1-(4-ethoxycarbonylaminobenzoyl)-3-(3-cyclo-pentyloxy-4-methoxyphenyl)-1,4,5,6-tetrahydro-pyridazine,

1-(3-ethoxycarbonylaminobenzoyl)-3-(3-cyclo-pentyloxy-4-methoxyphenyl)-1,4,5,6-tetrahydro-pyridazine,

1-(4-ethoxycarbonylaminobenzoyl)-3-(3,4-methylene-dioxyphenyl)-  
1,4,5,6-tetrahydropyridazine,

1-(4-ethoxycarbonylaminobenzoyl)-3-(3-methoxy-4-  
methylsulfonylphenyl)-1,4,5,6-tetrahydro-pyridazine,

1-(4-ethoxycarbonylaminobenzoyl)-3-(3-trifluoro-methoxy-4-  
methoxyphenyl)-1,4,5,6-tetrahydro-pyridazine,  
and the stereoisomers and physiologically acceptable salts and solvates  
thereof;

e) compounds disclosed in EP 0723962

3-(4-ethoxycarbonylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-  
dihydro-1,3,4-thiadiazin-2-one,

3-(4-ethoxycarbonylaminobenzyl)-5-(3-cyclopentyloxy-4-  
methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,  
and their physiologically acceptable salts and solvates;

f) compounds disclosed in EP 0738715

2-(4-butyrylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetra-  
hydropyridazin-3-one,

2-(4-acetamidobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydro-  
pyridazin-3-one,

2-(4-trifluoroacetamidobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-  
tetrahydropyridazin-3-one,

2-(4-methylsulfonamidobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-  
tetrahydropyridazin-3-one,

2-(4-propionylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-  
tetrahydropyridazin-3-one,

2-(4-tert-butylcarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,



2-(4-isobutyrylamino benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methoxycarbonylamino benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

5

2-(4-pivalylamino benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-cyclopentylcarbonyl benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

10

2-(4-ethoxycarbonylamino benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methoxalylamino benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

15

2-(4-ureido benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-pentanoylamino benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

20

2-(4-hexanoylamino benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-pentafluoropropionylamino benzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

25

2-(4-acetamidobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-trifluoroacetamidobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

30

2-(4-methylsulfonamidobenzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-propionylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-tert-butylcarbonylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

35

2-(4-butyrylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-isobutyrylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methoxycarbonylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

5 2-(4-pivalylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-cyclopentylcarbonyl benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

10 2-(4-ethoxycarbonylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methoxalylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

15 2-(4-ureido benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-pentanoylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

20 2-(4-hexanoylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-pentafluoropropionylamino benzyl)-6-(3,4-dimethoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

25 2-(4-acetamidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-trifluoroacetamidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

30 2-(4-methylsulfonamidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-propionylamino benzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

35 2-(4-butyrylamino benzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-isobutyrylamino benzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

- 2-(4-methoxycarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-pivalylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 5 2-(4-cyclopentylcarbamoylbenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-ethoxycarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one;
- 10 2-(4-methoxalylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-ureidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 15 2-(4-pentanoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-hexanoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 20 2-(4-pentafluoropropionylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-acetamidobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 25 2-(4-trifluoroacetamidobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-methylsulfonamidobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 30 2-(4-propionylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-tert-butylcarbonylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 2-(4-butyrylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,
- 35 2-(4-isobutyrylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methoxycarbonylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-pivalylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

5 2-(4-cyclopentylcarbamoylbenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-ethoxycarbonylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

10 2-(4-methoxalylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-ureidobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

15 2-(4-pentanoylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-hexanoylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

20 2-(4-pentafluoropropionylaminobenzyl)-6-(3-cyclopentyloxy-4-methoxyphenyl)-5-ethyl-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-acetamidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

25 2-(4-trifluoroacetamidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methylsulfonamidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

30 2-(4-propionylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-butyrylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

35 2-(4-isobutyrylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methoxycarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

2-(4-pivalylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetra-  
hydropyridazin-3-one,

2-(4-cyclopentylcarbamoylbenzyl)-6-(3-ethoxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,

5 2-(4-ethoxycarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,

2-(4-methoxalylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,

10 2-(4-ureidobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetra-  
hydropyridazin-3-one,

2-(4-pentanoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-  
2,3,4,5-tetrahydropyridazin-3-one,

15 2-(4-hexanoylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-  
tetrahydropyridazin-3-one,

2-(4-pentafluoropropionylaminobenzyl)-6-(3-ethoxy-4-methoxy-  
phenyl)-2,3,4,5-tetrahydropyridazin-3-one,

20 and their physiologically acceptable salts and solvates;

g) compounds disclosed in EP 0539806

25 5-(3-methoxy-4-difluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on,

5-(3-methoxy-4-trifluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on,

30 5-(3-methoxy-4-trifluormethoxyphenyl)-6-methyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on,

5-(3-methoxy-4-difluormethoxyphenyl)-6-methyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on,

35 5-[3-methoxy-4-(1,1,2,2-tetrafluoroethoxy)-phenyl]-6-ethyl-3,6-dihydro-  
1,3,4-thiadiazin-2-on,

5-(3-methoxy-4-chlormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-  
thiadiazin-2-on,

- 5-(3-methoxy-4-chlormethoxyphenyl)-6-methyl-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5-(3-methoxy-4-pentachlorethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5 5-(3-methoxy-4-trifluormethoxyphenyl)-6-propyl-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5-(3-methoxy-4-difluormethoxyphenyl)-6-propyl-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 10 5-[3-methoxy-4-(1,1,2,-trifluorethoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5-[3-methoxy-4-(1,1,2,-trifluorethoxy)-phenyl]-6-methyl-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 15 5-(3-methoxy-4-difluormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5-(3-methoxy-4-trifluormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 20 5-(4-trifluormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5-[3-methoxy-4-(1,1,2,2-tetrafluorethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5-(3-methoxy-4-chlormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 25 5-(3-methoxy-4-trichlormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5-(3-methoxy-4-pentachlorethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 30 5-(4-difluormethoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5-[3-methoxy-4-(1,1,2,2,3-pentafluoropropoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5-[bis-3,4-(difluormethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 35 5-[bis-3,4-(dichlormethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on,
- 5-[bis-3,4-(1,2-difluorethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on,

5-[3-ethoxy-4-(1,1,2,2-tetrafluoroethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on,

5-[3-methoxy-4-(1,2,2-trichloroethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on,

5 5-[4-(2,2,2-trifluoroethoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on,

5-[3-methoxy-4-(2,2,2-trifluoroethoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on,

10 5-[3-methoxy-4-(2,2,2-trifluoroethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazin-2-on,

5-[3-(2,2,2-trifluoroethoxy)-4-methoxy-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on,

15 5-(3-difluormethoxy-4-methoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazin-2-on,

and their physiologically acceptable salts and solvates;

20 h) compounds disclosed in EP 0618201

3-dimethylaminopropyl-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

25 3-dimethylaminopropyl-5-(3-methoxy-4-trifluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-dimethylaminopropyl-5-(3-methoxy-4-difluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

30 3-dimethylaminopropyl-5-(3-methoxy-4-fluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-dimethylaminopropyl-5-(4-methoxy-3-difluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

35 3-dimethylaminopropyl-5-[4-methoxy-3-(2,2,2-trifluoroethoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-dimethylaminopropyl-5-(4-methoxy-3-fluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-dimethylaminopropyl-5-(3-methoxy-4-ethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-dimethylaminopropyl-5-(4-methoxy-3-ethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

5 3-dimethylaminopropyl-5-(3-methoxy-4-hydroxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-dimethylaminopropyl-5-(3,4-dimethoxy-phenyl)-3,6-dihydro-1,3,4-thiadiazinon-2-on,

10 2-dimethylaminoethyl-5-(3,4-dimethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

2-dimethylaminoethyl-5-(3-methoxy-4-trifluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

15 2-dimethylaminoethyl-5-(3-methoxy-4-difluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

2-dimethylaminoethyl-5-(3-methoxy-4-fluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

20 2-dimethylaminoethyl-5-(4-methoxy-3-difluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

2-dimethylaminoethyl-5-(4-methoxy-3-fluormethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

25 2-dimethylaminoethyl-5-(3-methoxy-4-ethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

2-dimethylaminoethyl-5-(4-methoxy-3-ethoxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

30 2-dimethylaminoethyl-5-(4-methoxy-3-hydroxy-phenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-morpholinopropyl-5-[3-methoxy-4-(1,1,2,2,3-pentafluoropropoxy)-phenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

35 3-dimethylaminopropyl-5-[3,4-bis-(difluormethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-dimethylaminopropyl-5-[3-methoxy-4-(1,1,2-trifluoroethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazinon-2-on,



3-dimethylaminopropyl-5-[3,4-bis-(chloromethoxy)-phenyl]-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-morpholinopropyl-5-(3-methoxy-4-fluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

5 3-morpholinopropyl-5-(3-methoxy-4-trifluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-piperidinopropyl-5-(3-methoxy-4-difluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

10 3-morpholinopropyl-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-piperidinopropyl-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

15 3-pyrrolidinopropyl-5-(3,4-dimethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-morpholinopropyl-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

20 3-piperidinopropyl-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-pyrrolidinopropyl-5-(3-methoxy-4-ethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

25 3-morpholinopropyl-5-(4-methoxy-3-ethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-piperidinopropyl-5-(4-methoxy-3-ethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

30 3-morpholinopropyl-5-(3-methoxy-4-difluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-piperidinopropyl-5-(4-methoxy-3-difluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

35 3-piperidinopropyl-5-[3-(2,2,2-trifluoroethoxy)-4-methoxyphenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

3-morpholinopropyl-5-[3-(2,2,2-trifluoroethoxy)-4-methoxyphenyl]-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

2-morpholinoethyl-5-(3-methoxy-4-fluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

2-morpholinoethyl-5-(3-methoxy-4-trifluormethoxyphenyl)-6-ethyl-3,6-dihydro-1,3,4-thiadiazinon-2-on,

5 and their physiologically acceptable salts and solvates;

for preparing a medicament for treating a subject suffering from a disease or condition mediated by the PIDE4 isozyme in its role of regulating the activation and degranulation of human eosinophils.

3. Use according to claim 1 or 2 of compounds selected from

15 3-(4-nicotinoylaminobenzyl)-5-(3-ethoxy-4-methoxyphenyl)-3,6-dihydro-1,3,4-thiadiazin-2-one,

N-(3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazin-1-ylcarbonyl)phenyl)-4-methoxybenzoyl-3-carboxamide,

20 1-(4-nicotinoylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazine,

1-(4-ethoxycarbonylaminobenzoyl)-3-(3-ethoxy-4-methoxyphenyl)-1,4,5,6-tetrahydropyridazine,

25 2-(4-ethoxycarbonylaminobenzyl)-6-(3-ethoxy-4-methoxyphenyl)-2,3,4,5-tetrahydropyridazin-3-one,

and their physiologically acceptable salts and solvates;

for preparing a medicament for treating a subject suffering from a disease or condition mediated by the PDE4 isozyme in its role of regulating the activation and degranulation of human eosinophils.

4. Use of a compound as defined in claim 1, 2 or 3

35 for preparing a medicament in treating or preventing one or members selected from the groups of diseases, disorders, and conditions consisting of:

asthma of whatever type, etiology, or pathogenesis; or asthma that is a member selected from the group consisting of atopic asthma; non-atopic asthma; allergic asthma; atopic, bronchial, IgE-mediated asthma; bronchial asthma; essential asthma; true asthma; intrinsic asthma caused by  
5 pathophysiologic disturbances; extrinsic asthma caused by environmental factors; essential asthma of unknown or inapparent cause; non-atopic asthma; bronchitic asthma; emphysematous asthma; exercise-induced asthma; occupational asthma; infective asthma caused by bacterial,  
10 fungal, protozoal, or viral infection; non-allergic asthma; incipient asthma; wheezy infant syndrome;

chronic or acute bronchoconstriction; chronic bronchitis; small airways obstruction; and emphysema;

15 obstructive or inflammatory airways diseases of whatever type, etiology, or pathogenesis; or an obstructive or inflammatory airways disease that is a member selected from the group consisting of asthma; pneumoconiosis; chronic eosinophilic pneumonia; chronic obstructive pulmonary disease (COPD); COPD that includes chronic bronchitis,  
20 pulmonary emphysema or dyspnea associated therewith; COPD that is characterized by irreversible, progressive airways obstruction; adult respiratory distress syndrome (ARDS), and exacerbation of airways hyper-reactivity consequent to other drug therapy;

25 pneumoconiosis of whatever type, etiology, or pathogenesis; or pneumoconiosis that is a member selected from the group consisting of aluminosis or bauxite workers' disease; anthracosis or miners' asthma; asbestosis or steam-fitters' asthma; chalicosis or flint disease; ptilosis  
30 caused by inhaling the dust from ostrich feathers; siderosis caused by the inhalation of iron particles; silicosis or grinders' disease; byssinosis or cotton-dust asthma; and talc pneumoconiosis;

bronchitis of whatever type, etiology, or pathogenesis; or bronchitis that is a member selected from the group consisting of acute bronchitis;  
35 acute laryngotracheal bronchitis; arachidic bronchitis; catarrhal bronchitis; croupus bronchitis; dry bronchitis; infectious asthmatic bronchitis;

productive bronchitis; staphylococcus or streptococcal bronchitis; and vesicular bronchitis;

5           bronchiectasis of whatever type, etiology, or pathogenesis; or bronchiectasis that is a member selected from the group consisting of cylindric bronchiectasis; sacculated bronchiectasis; fusiform bronchiectasis; capillary bronchiectasis; cystic bronchiectasis; dry bronchiectasis; and follicular bronchiectasis;

10           seasonal allergic rhinitis; or perennial allergic rhinitis; or sinusitis of whatever type, etiology, or pathogenesis; or sinusitis that is a member selected from the group consisting of purulent or nonpurulent sinusitis; acute or chronic sinusitis; and ethmoid, frontal, maxillary, or sphenoid sinusitis,

15           rheumatoid arthritis of whatever type, etiology, or pathogenesis; or rheumatoid arthritis that is a member selected from the group consisting of acute arthritis; acute gouty arthritis; chronic inflammatory arthritis; degenerative arthritis; infectious arthritis; Lyme arthritis; proliferative arthritis; psoriatic arthritis; and vertebral arthritis;

20           gout, and fever and pain associated with inflammation;

          an eosinophil-related disorder of whatever type, etiology, or pathogenesis; or an eosinophil-related disorder that is a member selected from the group consisting of eosinophilia; pulmonary infiltration eosinophilia; Loffier's syndrome; chronic eosinophilic pneumonia; tropical  
25           pulmonary eosinophilia; bronchopneumonic aspergillosis; aspergilloma; granulomas containing eosinophils; allergic granulomatous angiitis 'or Churg-Strauss syndrome; polyarteritis nodosa (PAN); and systemic  
30           necrotizing vasculitis;

          atopic dermatitis; or allergic dermatitis; or allergic or atopic eczema;  
          urticaria of whatever type, etiology, or pathogenesis; or urticaria that  
          is a member selected from the group consisting of immune-mediated  
          urticaria; complement-mediated urticaria; urticariogenic material-induced  
35           urticaria; physical agent- induced urticaria; stressinduced urticaria;  
          idiopathic urticaria; acute urticaria; chronic urticaria; angioedema;

cholinergic urticaria; cold urticaria in the autosomal dominant form or in the acquired form; contact urticaria; giant urticaria; and papular urticaria;

conjunctivitis of whatever type, etiology, or pathogenesis; or  
conjunctivitis that is a member selected from the group consisting of actinic  
conjunctivitis; acute catarrhal conjunctivitis; acute contagious conjunctivitis;  
allergic conjunctivitis; atopic conjunctivitis; chronic catarrhal conjunctivitis;  
purulent conjunctivitis; and vernal conjunctivitis;

uveitis of whatever type, etiology, or pathogenesis; or uveitis that is a  
member selected from the group consisting of inflammation of all or part of  
the uvea; anterior uveitis; iritis; cyclitis; iridocyclitis; granulomatous uveitis;  
nongranulomatous uveitis; phacoantigenic uveitis; posterior uveitis;  
choroiditis; and chorioretinitis;

psoriasis;

multiple sclerosis of whatever type, etiology, or pathogenesis; or  
multiple sclerosis that is a member selected from the group consisting of  
primary progressive multiple sclerosis; and relapsing remitting multiple  
sclerosis;

autoimmune/inflammatory diseases of whatever type, etiology, or  
pathogenesis; or an autoimmune/inflammatory disease that is a member  
selected from the group consisting of autoimmune hematological  
disorders; hemolytic anemia; aplastic anemia; pure red cell anemia;  
idiopathic thrombocytopenic purpura; systemic lupus erythematosus;  
polychondritis; scleroderma; Wegner's granulomatosis; dermatomyositis;  
chronic active hepatitis; myasthenia gravis; Stevens-Johnson syndrome;  
idiopathic sprue; autoimmune inflammatory bowel diseases; ulcerative  
colitis; Crohn's disease; endocrinopathy; Grave's disease;  
sarcoidosis; alveolitis; chronic hypersensitivity pneumonitis; primary biliary  
cirrhosis; juvenile diabetes or diabetes mellitus type 1; anterior uveitis;  
granulomatous or posterior uveitis; keratoconjunctivitis sicca; epidemic  
keratoconjunctivitis; diffuse interstitial pulmonary fibrosis or interstitial lung  
fibrosis; idiopathic pulmonary fibrosis; cystic fibrosis; psoriatic arthritis;  
glomerulonephritis with and without nephrotic syndrome; acute

glomerulonephritis; idiopathic nephrotic syndrome; minimal change  
nephropathy; inflammatory/ hyperproliferative skin diseases; psoriasis;  
atopic dermatitis; contact dermatitis; allergic contact dermatitis; benign  
familial pemphigus; pemphigus erythematosus; pemphigus foliaceus; and  
5 pemphigus vulgaris;

prevention of allogeneic graft rejection following organ  
transplantation;

inflammatory bowel disease (IBD) of whatever type, etiology, or  
10 pathogenesis; or inflammatory bowel disease that is a member selected  
from the group consisting of ulcerative colitis (UC); collagenous colitis;  
colitis polyposa; transmural colitis; and Crohn's disease (CD);

septic shock of whatever type, etiology, or pathogenesis; or septic  
15 shock that is a member selected from the group consisting of renal failure;  
acute renal failure; cachexia; malarial cachexia; hypophyseal cachexia;  
uremic cachexia; cardiac cachexia; cachexia suprarenalis or Addison's  
disease; cancerous cachexia; and cachexia as a consequence of  
infection by the human immunodeficiency virus (HIV);

20 liver injury;

pulmonary hypertension; and hypoxia-induced pulmonary  
hypertension;

bone loss diseases; primary osteoporosis; and secondary  
25 osteoporosis;

central nervous system disorders of whatever type, etiology, or  
pathogenesis; or a central nervous system disorder that is a member  
selected from the group consisting of depression; Parkinson's disease;  
30 learning and memory impairment; tardive dyskinesia; drug dependence;  
arteriosclerotic dementia; and dementias that accompany Huntington's  
chorea, Wilson's disease, paralysis agitans, and thalamic atrophies;

infection, especially infection by viruses wherein such viruses  
35 increase the production of TNF- $\alpha$  in their host, or wherein such viruses are  
sensitive to upregulation of TNF- $\alpha$  in their host so that their replication or

other vital activities are adversely impacted, including a virus which is a member selected from the group consisting of HIV-1, HIV-2, and HIV-3; cytomegalovirus, CMV; influenza; adenoviruses; and Herpes viruses, including Herpes zoster and Herpes simplex;

5        yeast and fungus infections wherein said yeast and fungi are sensitive to upregulation by TNF- $\alpha$  or elicit TNF- $\alpha$  production in their host, e.g., fungal meningitis; particularly when administered in conjunction with other drugs of choice for the treatment of systemic yeast and fungus  
10       infections, including but are not limited to, polymyxins, e.g., Polymyxin B; imidazoles, e.g., clotrimazole, econazole, miconazole, and ketoconazole; triazoles, e.g., fluconazole and itraconazole; and amphotericins, e.g., Amphotericin B and liposomal Amphotericin B;

15       ischemia-reperfusion injury; autoimmune diabetes; retinal autoimmunity; chronic lymphocytic leukemia; HIV infections; lupus erythematosus; kidney and ureter disease; urogenital and gastrointestinal disorders; and prostate diseases.

20       5. Use according to claim 4 for preparing a medicament for the treatment of (1) inflammatory diseases and conditions comprising: joint inflammation, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, inflammatory bowel disease, ulcerative colitis, chronic glomerulonephritis,  
25       dermatitis, and Crohn's disease; (2) respiratory diseases and conditions comprising: asthma, acute respiratory distress syndrome, chronic pulmonary inflammatory disease, bronchitis, chronic obstructive airway disease, and silicosis; (3) infectious diseases and conditions comprising:  
30       sepsis, septic shock, endotoxic shock, gram negative, sepsis, toxic shock syndrome, fever and myalgias due to bacterial, viral or fungal infection, and influenza; (4) immune diseases and conditions comprising: autoimmune diabetes, systemic lupus erythematosus, graft vs. host reaction, allograft rejections, multiple sclerosis, psoriasis, and allergic  
35       rhinitis; and (5) other diseases and conditions comprising: bone resorption

- 111 -

diseases; reperfusion injury; cachexia secondary to infection or malignancy; cachexia secondary to human acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, or AIDS related complex (ARC); keloid formation; scar tissue formation; type 1 diabetes mellitus; and leukemia.

6. The combination of a compound as defined in Claim 1, 2 or 3 together with one or more members selected from the group consisting of the following:

(a) Leukotriene biosynthesis inhibitors, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxygenase activating protein (FLAP) antagonists selected from the group consisting of zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; *N*-(5-substituted)-thiophene-2-alkylsulfonamides; 2,6-di-*tert*-butylphenol hydrazones; Zeneca ZD-2138; SB-210661; pyridinyl-substituted 2-cyanonaphthalene compound L-739,010; 2-cyanoquinoline compound L-746,530; indole and quinoline compounds MK-591, MK-886, and BAY x 1005;

(b) Receptor antagonists for leukotrienes LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub> selected from the group consisting of phenothiazin-3-one compound L-651,392; amidino compound CGS-25019c; benzoxazamine compound ontazolast; benzenecarboximidamide compound BIII 284/260; compounds zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195;

(c) PDE4 inhibitors;

(d) 5-Lipoxygenase (5-LO) inhibitors; and 5-lipoxygenase activating protein (FLAP) antagonists;



- 112 -

- (e) Dual inhibitors of 5-lipoxygenase (5-LO) and antagonists of platelet activating factor (PAF);
- 5 (f) Leukotriene antagonists (LTRAs) of LTB<sub>4</sub>, LTC<sub>4</sub>, LTD<sub>4</sub>, LTE<sub>4</sub>;
- (g) Antihistaminic H<sub>1</sub> receptor antagonist cetirizine, loratadine, desloratadine, fexofenadine, astemizole, azelastine, and chlorpheniramine;
- 10 (h) Gastroprotective H<sub>2</sub> receptor antagonists;
- (i)  $\alpha_1$ - and  $\alpha_2$ -adrenoceptor agonist vasoconstrictor sympathomimetic agents administered orally or topically for decongestant use, selected from
- 15 the group consisting of propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline, hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride;
- 20 (j) one or more  $\alpha_1$ - and  $\alpha_2$ -adrenoceptor agonists as recited in (i) above in combination with one or more inhibitors of 5-lipoxygenase (5-LO) as recited in (a) above;
- 25 (k) Anticholinergic agents ipratropium bromide; tiotropium bromide, oxitropium bromide; pirenzepine; and telenzepine;
- (l)  $\beta_1$ - to  $\beta_2$ -adrenoceptor agonists selected from the group consisting
- 30 of metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol, and pirbuterol;
- (m) Theophylline and aminophylline;
- 35 (n) Sodium cromoglycate;

- 113 -

- (o) Muscarinic receptor (M1, M2, and M3) antagonists;
- 5 (p) COX-1 inhibitors (NSAIDs); and nitric oxide NSAIDs;
- (q) COX-2 selective inhibitor rofecoxib;
- 10 (r) Insulin-like growth factor type I (IGF-1) mimetics;
- (s) Ciclesonide;
- 15 (t) Inhaled glucocorticoids with reduced systemic side effects selected from the group consisting of prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, and mometasone furoate;
- 20 (u) Tryptase inhibitors;
- (v) Platelet activating factor (PAF) antagonists;
- 25 (w) Monoclonal antibodies active against endogenous inflammatory entities;
- (x) IPL 576;
- 30 (y) Anti-tumor necrosis factor (TNF $\alpha$ ) agents selected from the group consisting of etanercept, infliximab, and D2E7;
- (z) DMARDs selected from the group consisting of leflunomide;
- 35 (aa) TCR peptides;

- (bb) Interleukin converting enzyme (ICE) inhibitors;
- 5 (cc) IMPDH inhibitors;
- (dd) Adhesion molecule inhibitors including VLA-4 antagonists;
- 10 (ee) Cathepsins;
- (ff) MAP kinase inhibitors;
- (gg) Glucose-6 phosphate dehydrogenase inhibitors;
- 15 (hh) Kinin-B<sub>1</sub>- and B<sub>2</sub>-receptor antagonists;
- (ii) Gold in the form of an aurothio group in combination with hydrophilic groups;
- 20 (jj) Immunosuppressive agents selected from the group consisting of cyclosporine, azathioprine, and methotrexate;
- 25 (kk) Anti-gout agents selected from the group consisting of colchicines;
- (ll) Xanthine oxidase selected from the group consisting of allopurinol;
- 30 (mm) Uricosuric agents selected from the group consisting of probenecid, sulfinpyrazone, and benzbromarone;
- (nn) Antineoplastic agents that are antimitotic drugs selected from the group consisting of vinblastine and vincristine;
- 35 (oo) Growth hormone secretagogues;

5 (pp) Inhibitors of matrix metalloproteases (MMPs) that are selected from the group consisting of the stromelysins, the collagenases, the gelatinases, aggrecanase, collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11);

10 (qq) Transforming growth factor (TGF $\beta$ );

(rr) Platelet-derived growth factor (PDGF);

15 (ss) Fibroblast growth factor selected from the group consisting of basic fibroblast growth factor (bFGF);

(tt) Granulocyte macrophage colony stimulating factor (GM-CSF);

20 (uu) Capsaicin;

(vv) Tachykinin NK<sub>1</sub> and NK<sub>3</sub> receptor antagonists selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418;

25 (ww) Elastase inhibitors selected from the group consisting of UT-77 and ZD-0892;

and

30 (xx) Adenosine A2a receptor agonists.

35

## INTERNATIONAL SEARCH REPORT

Inter Application No

PCT/EP 02/09596

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/54 A61K31/495 A61K31/50 A61P11/06 A61P17/06  
 A61P29/00 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 199 32 315 A (MERCK PATENT GMBH) 11 January 2001 (2001-01-11) cited in the application abstract page 2, line 35 - line 63 formulae I-VII	1-5
Y	page 6, line 34	6
X	WO 00 59890 A (KLUXEN FRANZ WERNER ; MERCK PATENT GMBH (DE); BEIER NORBERT (DE); F) 12 October 2000 (2000-10-12) cited in the application abstract formula I	1-5
Y	page 11, line 4 - line 27 page 11, line 1 - line 2	6
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

9 January 2003

Date of mailing of the international search report

23/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Villa Riva, A

## INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/EP 02/09596

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 65880 A (KLUXEN FRANZ WERNER ;MERCK PATENT GMBH (DE); JONAS ROCHUS (DE); WO) 23 December 1999 (1999-12-23) cited in the application abstract formula I page 2, line 19 -page 3, line 23	1-5
Y	page 12, line 6 - line 7 ---	6
X	WO 98 06704 A (KLUXEN FRANZ WERNER ;MERCK PATENT GMBH (DE); BEIER NORBERT (DE); R) 19 February 1998 (1998-02-19) cited in the application abstract formula I page 10, line 34 -page 11, line 5	1-5
Y	page 10, line 2 - line 5 ---	6
X	DE 196 04 388 A (MERCK PATENT GMBH) 14 August 1997 (1997-08-14) cited in the application abstract formula I page 7, line 1 - line 2	1-5
Y	page 6, line 47 ---	6
X	EP 0 763 534 A (MERCK PATENT GMBH) 19 March 1997 (1997-03-19) cited in the application abstract examples formula I page 7, line 1 - line 2	1-5
Y	page 6, line 39 ---	6
X	EP 0 738 715 A (MERCK PATENT GMBH) 23 October 1996 (1996-10-23) cited in the application abstract formula I page 7, line 25 - line 26 examples	1-5
Y	page 7, line 4 ---	6
X	EP 0 723 962 A (MERCK PATENT GMBH) 31 July 1996 (1996-07-31) cited in the application abstract page 2, line 45 - line 50 examples	1-5
Y	page 5, line 54 - line 55 ---	6
	--- -/--	

## INTERNATIONAL SEARCH REPORT

Interr      Application No

PCT/EP 02/09596

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 618 201 A (MERCK PATENT GMBH) 5 October 1994 (1994-10-05) cited in the application abstract formula I page 2, line 42 - line 43 examples	1-5
Y	page 6, line 40	6
Y	TEIXEIRA M M ET AL: "Mechanisms and pharmacological manipulation of eosinophil accumulation in vivo" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 16, no. 12, December 1995 (1995-12), pages 418-423, XP004207566 ISSN: 0165-6147 the whole document	1-6
Y	TEIXEIRA M M ET AL: "Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 18, no. 5, 1 May 1997 (1997-05-01), pages 164-170, XP004094497 ISSN: 0165-6147 the whole document	1-6
Y	ALVES ALESSANDRA C ET AL: "Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro." EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 312, no. 1, 1996, pages 89-96, XP002226623 ISSN: 0014-2999 the whole document	1-6
Y	WO 01 32127 A (GOODFELLOW PETER N ;SMITHKLINE BEECHAM CORP (US); TORPHY THEODORE) 10 May 2001 (2001-05-10) abstract page 2, line 7 - line 15	6
Y	WO 01 58441 A (KEATING ELIZABETH T ;SMITHKLINE BEECHAM CORP (US); KANAGY JAMES M) 16 August 2001 (2001-08-16) abstract page 2, line 5 - line 14	6

## INTERNATIONAL SEARCH REPORT

Intern Application No

PCT/EP 02/09596

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
DE 19932315	A	11-01-2001	DE 19932315 A1	11-01-2001
			AU 6688300 A	30-01-2001
			CN 1360581 T	24-07-2002
			CZ 20020012 A3	17-04-2002
			WO 0104099 A1	18-01-2001
			EP 1194411 A1	10-04-2002
			NO 20020096 A	09-01-2002
			SK 72002 A3	09-05-2002
WO 0059890	A	12-10-2000	DE 19915365 A1	12-10-2000
			AU 3289700 A	23-10-2000
			WO 0059890 A1	12-10-2000
WO 9965880	A	23-12-1999	DE 19826841 A1	23-12-1999
			AU 750019 B2	11-07-2002
			AU 4259099 A	05-01-2000
			BR 9911177 A	13-03-2001
			CA 2335104 A1	23-12-1999
			CN 1305465 T	25-07-2001
			WO 9965880 A1	23-12-1999
			EP 1087946 A1	04-04-2001
			HU 0102215 A2	28-03-2002
			JP 2002518377 T	25-06-2002
			NO 20006412 A	15-12-2000
			PL 344796 A1	19-11-2001
			SK 18932000 A3	11-06-2001
			US 6417188 B1	09-07-2002
WO 9806704	A	19-02-1998	DE 19632549 A1	19-02-1998
			AU 725652 B2	19-10-2000
			AU 4013397 A	06-03-1998
			BR 9711066 A	17-08-1999
			CN 1227547 A	01-09-1999
			CZ 9900493 A3	12-05-1999
			WO 9806704 A1	19-02-1998
			EP 0922036 A1	16-06-1999
			HU 0001760 A2	28-05-2001
			JP 2001503022 T	06-03-2001
			KR 2000029921 A	25-05-2000
			NO 990676 A	12-02-1999
			PL 331557 A1	19-07-1999
			SK 16899 A3	10-12-1999
			TW 427980 B	01-04-2001
			US 6479494 B1	12-11-2002
			ZA 9707206 A	12-11-1999
DE 19604388	A	14-08-1997	DE 19604388 A1	14-08-1997
EP 0763534	A	19-03-1997	DE 19533975 A1	20-03-1997
			AU 716113 B2	17-02-2000
			AU 6551796 A	20-03-1997
			BR 9603736 A	26-05-1998
			CA 2185397 A1	15-03-1997
			CN 1157287 A	20-08-1997
			CZ 9602630 A3	18-03-1998
			EP 0763534 A1	19-03-1997
			HU 9602511 A2	28-03-1997
			JP 9124611 A	13-05-1997



## INTERNATIONAL SEARCH REPORT

 Inter Application No  
 PCT/EP 02/09596

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0763534	A	NO 963852 A	17-03-1997
		PL 316070 A1	17-03-1997
		RU 2167159 C2	20-05-2001
		SK 110096 A3	06-08-1997
		US 5859008 A	12-01-1999
		ZA 9607766 A	26-03-1997
EP 0738715	A	23-10-1996	
		DE 19514568 A1	24-10-1996
		AU 705025 B2	13-05-1999
		AU 5071196 A	31-10-1996
		CA 2174472 A1	21-10-1996
		CN 1142493 A	12-02-1997
		CZ 9601132 A3	13-11-1996
		EP 0738715 A2	23-10-1996
		HU 9601034 A2	30-12-1996
		JP 8291145 A	05-11-1996
		NO 961578 A	21-10-1996
		RU 2159236 C2	20-11-2000
		SK 48796 A3	05-02-1997
		TW 475927 B	11-02-2002
		US 2002111356 A1	15-08-2002
		US 6399611 B1	04-06-2002
		ZA 9603154 A	06-12-1996
EP 0723962	A	31-07-1996	
		DE 19502699 A1	01-08-1996
		AT 202775 T	15-07-2001
		AU 705639 B2	27-05-1999
		AU 4211196 A	08-08-1996
		CA 2168193 A1	29-07-1996
		CZ 9600251 A3	14-08-1996
		DE 59607188 D1	09-08-2001
		DK 723962 T3	29-10-2001
		EP 0723962 A1	31-07-1996
		ES 2160184 T3	01-11-2001
		GR 3036343 T3	30-11-2001
		HU 73981 A2	28-10-1996
		JP 8231522 A	10-09-1996
		NO 960352 A	29-07-1996
		PL 312489 A1	05-08-1996
		PT 723962 T	31-10-2001
		RU 2161613 C2	10-01-2001
		SI 723962 T1	31-12-2001
		SK 12396 A3	01-10-1996
		US 6025354 A	15-02-2000
		US 5747489 A	05-05-1998
		ZA 9600630 A	15-08-1996
EP 0618201	A	05-10-1994	
		DE 4310699 A1	06-10-1994
		AU 675488 B2	06-02-1997
		AU 5798394 A	06-10-1994
		CA 2120301 A1	02-10-1994
		CN 1101644 A	19-04-1995
		CZ 9400705 A3	15-12-1994
		EP 0618201 A1	05-10-1994
		HU 70543 A2	30-10-1995
		JP 7002812 A	06-01-1995
		NO 941150 A	03-10-1994
		SK 38594 A3	07-12-1994

## INTERNATIONAL SEARCH REPORT

Intern: Application No

PCT/EP 02/09596

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0618201	A	US 5434149 A	18-07-1995
WO 0132127	A	10-05-2001	
		AU 1357501 A	14-05-2001
		BR 0015270 A	18-06-2002
		EP 1225866 A2	31-07-2002
		NO 20022057 A	27-06-2002
		TR 200201211 T2	21-08-2002
		WO 0132127 A2	10-05-2001
WO 0158441	A	16-08-2001	
		AU 7205701 A	20-08-2001
		BR 0108087 A	29-10-2002
		EP 1253919 A1	06-11-2002
		NO 20023737 A	27-09-2002
		WO 0158441 A1	16-08-2001